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Abstract 
 
Introduction: Factors and other stimuli that lead to the release of basic fibroblast 
growth factor (bFGF) from endothelial cells may be essential for physiological 
processes such as development and angiogenesis. The release mechanisms are 
somewhat obscure and it has previously been shown that in the case of shear stress 
induced bFGF release cell matrix interaction is critically mediating that bFGF release 
(Gloe et al., 2002). Considering the potential role of proteolytically modified extra-
cellular matrix components in the induction of cellular signaling cascades, the aim of 
the present study was to investigate whether elastase activity contributes to the 
release of bFGF from endothelial cells.  
Methods and results: Treatment of porcine aortic endothelial cells with elastase led to 
a release of bFGF in a concentration-dependent manner. This release was strictly 
regulated and could be reduced by inhibition of integrin αvβ3. Moreover, bFGF was 
translocated towards the cell membrane after elastase treatment as well as shear 
stress exposure, in close proximity to HSP27. Furthermore, elastase treatment led to a 
p38 MAP Kinase dependent HSP27 phosphorylation and this phospho-HSP27 could 
be shown to co-precipitate with bFGF.  
Conclusion: We conclude that elastolytic activities activated by shear stress are 
involved in the active release of bFGF from endothelial cells and that 
phosphorylation of HSP27 is prerequisite for this release mechanism. The results may 
reflect the critical role of proteases in the initial process of angiogenesis induction. 
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Abbreviation 
 
A:  Ampere 
ABC:  ATP-binding cassette 
Abx:  Abciximab 
App:  Approximately 
AP-1:  Activator protein-1 
APS:  Ammoniumpersulfate 
BAEC:  Bovine Aorta Endothelial Cells 
BCA:  Bicinchoninic Acid 
bFGF:  Basic fibroblast growth factor 
BSA:  Bovine serum albumin 
Da:  Dalton 
DAG:  Diacylglycerol 
dH2O:  Distillated water 
DMEM: Dulbecco’s modification of Eagle’s medium 
ECL:  Enhanced Chemoluminescence reagent 
ECM:  Extracellular matrix 
Ela:  Elastase 
ELISA:  Enzym-linked immunosorbe 
ER:  Endoplasmatic reticulum 
ERK:  Extracellular signaling-regulated kinase 
FACE:  Fast activated cell based ELISA 
FACS:  Fluorescence activated cell sorter  
FAK:  Focal adhesion kinase 
FCS:  Fetal calf serum 
FGFR:  bFGF receptor 
FITC:  Fluoresceinisothiocyanate 
FRS2:  FGF receptor substrate 2 
GTP:  Guanosine triphosphate 
H2O2:  Hydrogen peroxide 
HRP:  Horseradish peroxidase 
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HS:  Heparan sulfate 
HSP:  Heparan sulfate proteoglycan 
HSP27:  Heat shock protein 27 
HUVEC: Human Umbilical Vein Endothelial cells 
IEF:  Isoelectric focusing 
IG:  Immunoglobulin 
JNK:  c-Jun NH2-terminal protein kinase 
L:  Liter 
L-15:  Leibovitz medium 
m:  Milli 
M:  Molar 
MAPK:  Mitogen activated protein kinase 
MAPKAPK: Mitogen activated protein kinase activated protein kinase 
Min:  Minute 
mRNA: messenger Ribonucleinic acid  
n:  Nano 
NF-κB:  Nuclear Factor κB 
NOS:  Nitric oxide synthase 
NS:  Non-significant 
OD:  Optical Density 
p:  Pico  
PACE:  Phosphospecific antibody cell-based ELISA 
PAEC:  Porcine Aorta Endothelial Cells 
PAGE:  Polyacrylamide-gel electrophoresis 
Perm:  Permeable 
PBS:  Phosphate-buffered saline 
PECAM: Platelet/endothelial cell adhesion molecule 
PI:  Propidium iodide  
PIP2:  Phosphatidylionsitol 4,5-biphosphate 
PKC:  Protein kinase C 
PLCγ:  Phospholipase Cγ 
PTK:  protein tyrosin kinase  
rpm:  Rounds per minute  
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PRAK:  p38 regulated and –activated protein kinase 
RT:  Room temperature 
µ:  Micro 
SDS:  Sodium dodecyl sulfate 
Sec:  Second 
SEM:  Standard error of the mean value  
SRP:  Signal-recognition particle 
TEMED: N,N,N’,N’-tetramethylethylendiamine  
TK:  Tyrosine kinase 
TBS-T:  Phosphate buffered saline solution with Tween 20  
TGF-β3: Transforming growth factor-beta 3 
TM:  Transmembrane 
TNF-α:  Tumor necrosis factor alpha 
Tris:  Tris-hydrozymethyl-aminomethan 
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Background 
 
Angiogenesis is a fundamental process in reproduction and wound healing and is 
prerequisite in placental development and tumor growth (Liekens et al., 2001;Prior et 
al., 2004). It is a complex process consisting of different sequential steps, which 
include the release of proteases from endothelial cells with subsequent degradation 
of the basement membrane surrounding the pre-existing vessels, migration of 
endothelial cells into the interstitial space, endothelial cell proliferation and 
differentiation into mature blood vessels. For these processes to proceed, an 
extensive interplay between cells, angiogenic inducers and extracellular matrix 
components is necessary. Among angiogenic factors are the “basic fibroblast 
growth factor” (bFGF) and “vascular endothelial growth factor “(VEGF) the most 
important and best characterized (Liekens et al., 2001).  
 VEGF is expressed in different tissues and by many cells and it acts specifically on 
endothelial cells (Veikkola & Alitalo, 1999). In vitro, VEGF stimulates degradation of 
the extracellular matrix, and migration, proliferation, and tube formation of 
endothelial cells. In vivo, the VEGF has been shown to regulate vascular 
permeability, which is essential for the initiation of angiogenesis (Liekens et al., 2001).  
 Like VEGF, bFGF induces processes in vitro, which are critical for angiogenesis. Basic 
FGF stimulates endothelial cell proliferation, migration and production of urokinase-
type plasminogen activator, and it induces tube formation in collagen gels (Papetti 
& Herman, 2002; Liekens et al., 2001). In contrast to VEGF, bFGF does not only act on 
endothelial cells, but stimulates proliferation of almost all cell types (Papetti & 
Herman, 2002). Furthermore, bFGF is not only important in angiogenesis, but is a 
pleiotropic protein that can exert multiple functions on a variety of cells (Bikfalvi et 
al., 1997; Nugent & Iozzo, 2000; Chen et al., 2004). Basic FGF is distinguished from 
most other proteins by the fact that it lacks the signal sequence needed for classical 
protein export from cells. Hence, the release of the protein still needs to be 
elucidated, which makes bFGF a unique and very interesting protein. 
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Basic fibroblast growth factor (bFGF) 
 
In the early 1970s, Gospodarowicz and his co-workers purified a protein from bovine 
pituitary gland, which was capable of inducing proliferation and phenotypic 
transformation of BALB/c 3T3 fibroblast (Gospodarowicz, 1974; Gospodarowicz et al., 
1974; Gospodarowicz, 1975). This protein was named “basic fibroblast growth factor” 
(bFGF), because of its basic isoelectric point of 9.6. Some years later another FGF-
related protein was recognized and named acidic FGF (aFGF), again, based upon 
its isoelectric point of 5.6 (Miller et al., 2000). Since then, many other FGFs have been 
purified and cloned and in 1991, when identification of 7 FGFs had been made, the 
aFGF and bFGF were renamed to FGF-1 and FGF-2, respecitively, however the 
original names of the two first isolated FGFs were preserved for historical reasons 
(Chen et al., 2004). At the same time it was emphasized that the name FGF did not 
mean that the major task of these protein was stimulation of fibroblast proliferation. 
To date 22 members of the FGF family have been identified in humans and 
vertebrates (Ornitz & Itoh, 2001). 
 In the following I will address structural, chemical and functional properties of bFGF 
and focus on its non-classical secretion from the producing cells. 
 
Structure 
 
Since 1975, the primary structure of bFGF has been sequenced and its cDNA cloned 
(Abraham et al., 1986b). The sequence homology for bFGF across a wide range of 
species is very high (>90%) (Nugent & Iozzo, 2000), in particular, the sequence of 
human bFGF is 99% homologous to that of the bovine bFGF (Abraham et al., 1986b). 
The human genome has only one copy of the bFGF gene (fgf2), which has been 
mapped to band q26-q27 on the human chromosome 4 (Dow & deVere White, 
2000; Okada-Ban et al., 2000). The size of the gene is 40 kilobases and the coding 
sequence consists of three exons, which are interrupted by two introns (Abraham et 
al., 1986b) (figure 1A). Fgf2 is a unique gene and differ from most eukaryotic genes in 
the way that it lacks the CAAT and TATA box motifs found in the promoters of most 
genes (Shibata et al., 1991). Instead its promoter contains activator protein-1 (AP-1) 
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binding sites and five GC boxes, but the functional relevance of these sites is not yet 
defined (Chen et al., 2004). 
 An AUG codon on the bFGF cDNAs was found to initiate translation of a protein of 
155 amino acids and no in frame AUG codons were found upstream (Bikfalvi et al., 
1997). Hence, the translation was predicted to initiate at this AUG codon. However, 
higher molecular weight forms (196, 201 and 210 amino acids) were found later 
(Bikfalvi et al., 1997), and recently an even longer isoform has been identified (288 
amino acids) (Arnaud et al., 1999) (figure 2). Four alternative CUG codons, 5’ to the 
Figure 1: Schematic representation of the structure of bFGF (A) and its receptor, FGFR2 (B). 
(A) The bFGF gene does not have CAAT or TATA boxes, but consists instead of the promoter, 
which includes a transcription factor AP-1 (activator protein-1) and five GC boxes forming a 
SP-1 binding site. (B) The bFGF receptor has three extracellular immunoglobulin (IG) 
domains, a transmembrane (TM) domain and two intracellular tyrosine kinase (TK1-2) 
domains. Note that bFGF binds to the IIIc isoform of the IG loop3. The binding affinity of bFGF 
for its receptor increases when proteoglycans (PG), eg. heparan sulfate (HS) and heparan 
sulfate proteoglycans (HSP), are bound to bFGF ligand. Modified after Dow & deVere White, 
2000. 
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AUG codon used for translation of the 155-amino acid form, were used as initiation 
codons for the high molecular weight forms (Florkiewicz & Sommer, 1989; Arnaud et 
al., 1999). The different isoforms of the bFGF protein migrate on a SDS-PAGE gel with 
molecular masses of 18 kDa for the AUG-initiated form and 22, 22.5, 24 and 34 kDa 
for the CUG-initiated forms (Bikfalvi et al., 1997; Arnaud et al., 1999).  
 The bFGF proteins initiated at AUG (18 kDa) are primary localized in the cytoplasm, 
whereas the CUG-initiated forms (22, 22.5 and 24 kDa) are predominantly found in 
the nucleus (Quarto et al., 1991; Florkiewicz et al., 1991; Bugler et al., 1991). The signal 
sequence responsible for the nuclear localization of the high molecular forms of 
Figure 2: (A) The different isoforms of bFGF as a result of alternative translation. The upper 
panel, shows the human mRNA and codons for translation. In the lower panel the bFGF 
isoforms are shown, 18, 22, 22.5, 24 and 34 kDa-FGF. The red boxes are the nuclear 
localization signal (NLS). (B) Structure of the human 18 kDa- bFGF (155 amino acids). The 
receptor (cell) binding domain and heparin binding domain are indicated Modified after 
Okada-Ban et al., 2000. 
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bFGF derives specifically from a 37 amino acids residue between the last CUG and 
the AUG start codons within the NH2-terminal extension (Quarto et al., 1991; Bugler et 
al., 1991) (figure 2). Furthermore, the 34 kDa bFGF has an additional nuclear 
localization signal (NLS) between the first and the second CUG start codon (Arnaud 
et al., 1999) (figure 2). However, nuclear occurrence of the 18 kDa isoform has been 
reported, suggesting a NLS in the 28 kDa sequence (Claus et al., 2003). 
 Basic FGF interacts with low-affinity heparin or heparin sulfate proteoglycan (HSPG), 
which is prerequisite to the biological activity of growth factor (Ornitz & Itoh, 2001). 
HSPGs are found on cell surfaces and in the extracellular matrix, where their 
interaction with bFGF stabilizes the growth factor and facilitates its binding to the 
high-affinity transmembrane FGF receptors (Nugent & Iozzo, 2000; Yayon et al., 1991). 
Four major FGF receptor families have been identified: FGFR1-4 (Jaye et al., 1992). 
The FGF receptors consist of an extracellular ligand binding domain, a single 
transmembrane domain, and an intracellular tyrosine kinase (TK) domain (Ornitz et 
al., 1996) (figure 1B). The extracellular domain, which consist of three 
immunoglobulin-like domains (IG loop 1-3), determines the ligand binding specificity 
and mediates ligand-induced receptor dimerization (Ornitz et al., 1996; Lee et al., 
1989). Basic FGF binds to FGFR2 where it has two distinct receptor binding sites, one 
at the IG loop 2 and another at the interloop region of IG loop 2. Alternative mRNA 
splicing creates the IIIb and IIIc isoform of the FGFR2, where bFGF only binds to the 
IIIc isoform (Dow & deVere White, 2000). The bFGF activation of its receptor induces 
FGFR2 dimerization and subsequently autophosphorylation which initiates signaling 
cascades.  
 
Basic FGF signaling pathways 
 
After binding to its receptor, bFGF activates a number of intracellular pathways 
(Nugent & Iozzo, 2000). Here only the most well characterized processes that have 
been shown to exist in a variety of different cell types will be mentioned (figure 3). 
Briefly, the proteins FRS2 (FGF receptor substrate 2) and SHC are binding to the 
phosphotyrosine residue of the bFGF receptor and function as docking protein for 
the GRB2-SOS complex, which can activate RAS and subsequently initiate the Raf-
MEK-MAPK cascade (Pintucci et al., 2002). The MAPK translocates to the nucleus, 
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where it activates transcription factors by phosphorylation. Moreover, phospholipase 
Cγ (PLCγ) binds also to the phosphotyrosine residue and is activated during bFGF 
receptor binding. By activation it initiates a signaling cascade via hydrolysis of 
phosphatidylinositol to inositol-3-phosphate and diacylglycerol (DAG) leading to 
calcium release and activation of protein kinase C (PKC), which is implicated in a 
variety of cell functions. Moreover, bFGF has also been shown to be internalized via 
the cell surface receptors and subsequently translocated and accumulated in the 
nucleolus, where it is, among others, thought to stimulate the transcription of 
ribosomal genes during G0→G1 transition in the cell cycle (Chen et al., 2004).  
 The binding of bFGF to its receptor as well as internalization of the growth factor is 
critically dependent upon binding to HSPG, as mentioned earlier, therefore it is 
PLCγSC
H
FSR
2
GRB-2
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RAS GTP
GDP+
P
Raf
MEK
MAPK
MAPK
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Ca2+
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P
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P
P
P
P
↑jun, 
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Figure 3: Schematic illustration of bFGF signaling pathway. Basic FGF can 
activate a number of different intracellular pathways. Here, only the major 
well characterized processes found in different cell types are shown. Man 
effector proteins have been left out in order to keep it clear. Modified after 
Nugent & Iozzo, 2000. See text for explanations. 
 
Introduction 
 15 
speculated that beside the FGF receptor expressed the type of cellular response is 
modulated by the specific cell surface HSPG (Nugent & Iozzo, 2000).  
 
Biological function 
 
Basic FGF plays key roles in development, remodeling and disease states in almost 
every organ system (Bikfalvi et al., 1997) (table 1). The many effects displayed by 
bFGF indicate the importance of the growth factor in regulation of developmental 
and physiological activities. Surprisingly, the bFGF knockout mice lacking all isoforms 
are viable, fertile and are grossly phenotypically similar to the wildtype mice. 
However, the knockout animals have some mild defects including delayed wound 
healing, decreased neuronal density in the motor cortex and reduced blood 
pressure (Dono et al., 1998; Miller et al., 2000; Ortega et al., 1998; Zhou et al., 1998). I 
will in the following focus on the role of bFGF in the vascular system.  
 
 
Tab le 1:  Function of bFGF in different organ systems. Modified after Bikfalvi et al., 1997 
Organ Functions 
Blood vessel 
Angiogenesis, smooth muscle cell proliferation, Atherogenesis, 
blood pressure control 
Brain Neuronal differentiation and survival 
Lung Branching morphogenesis, fibrosis 
Limb Limb development 
Muscle Myogenesis 
Bone Osseous healing, chondrogenesis 
Hematopoiesis 
Stimulation of granuloiesis, megakaruocytopoiesis, stem cell 
survival, anti-apoptotic effect 
Reproductive system Spermatogenesis 
Eye Photoreceptor survival and transduction 
Skin 
Melanogenesis 
Morphogenesis of the suprabassal keratinocytes 
Tissue repair 
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bFGF in angiogenesis and vascular remodeling 
 
Basic FGF induces migration, proliferation and differentiation of endothelial cells in 
vitro, and hence, it is thought to play an important role in angiogenesis (Dow & 
deVere White, 2000; Bikfalvi et al., 1997). Furthermore, bFGF has been shown to 
regulate the expression of several proteins, including interstitial collagenase, 
urokinase type plasminogen activator (uPa) and β1 integrins, all of which are 
important for the invasion of endothelial cells into the matrix during angiogenesis 
(Bikfalvi et al., 1997). In line with these observations, clinical studies have 
demonstrated that local as well as systemical injection of bFGF leads to enhanced 
myocardial collateral flow (Unger et al., 1994; Lazarous et al., 1995; Rajanayagam et 
al., 2000). Moreover, a recent study was able to show that the bFGF concentration in 
collateral arteries of patients with chronic total coronary occlusion was higher then in 
the aortic root, implying a role of bFGF in collateral development and function in 
those patients (Werner et al., 2004).  
 Besides bFGF, vascular endothelial growth factor (VEGF) has also been shown to 
display angiogenetic properties (Ferrara, 2000), and in fact, combined administration 
of VEGF and bFGF results in greater and more rapid increase of collateral circulation 
compared with administration of either VEGF or bFGF alone (Asahara et al., 1995). 
Basic FGF has previously been considered the primary tumor angiogenesis factor 
(Bikfalvi et al., 1997). This was based upon observations such as elevated bFGF 
activity in the cerebrospinal fluid of patients with brain tumor and in the urine of 
patients with solid tumors or leukemias (Bikfalvi et al., 1997).  
 Basic FGF can induce smooth muscle cell proliferation (Bikfalvi et al., 1997) and has 
been identified as an important factor in vascular remodeling. Studies suggest that 
bFGF increases vascular tone (Bryant et al., 1999), a proposal, which is substantiated 
by the observation that bFGF deficit mice have reduced vascular tone and as a 
consequence these animals have a low blood pressure (Zhou et al., 1998; Dono et 
al., 1998). In contrast, Brown et. al concluded from experiments done by electric 
stimulation of muscles in rats that bFGF is a regulator of blood flow by acting as a 
dilator of small arterioles (Brown et al., 1998) which is supported by the study 
demonstrating that the diameters of the arterioles in the hamster creek pouch were 
elevated as a response to bFGF application (Brown et al., 1996). Different setups in 
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the different studies can be the explanation for the contradictory observations of the 
implications of bFGF on the vascular system. 
 
bFGF secretion 
 
Basic FGF can display its biological activities by acting as a paracrine (Dow & 
deVere White, 2000; Seghezzi et al., 1998), an autocrine (Mignatti et al., 1991; 
Seghezzi et al., 1998) as well as an intracrine factor (Chen et al., 2004). For bFGF to 
act as an autocrine or a paracrine factor it must be released from the producing 
cells. However, the striking feature of bFGF is that it lacks a hydrophobic signal 
sequence, which is needed for secretion via the classical endoplasmatic reticulum-
Golgi system (see the following section) (Abraham et al., 1986a; Mignatti et al., 1992; 
Florkiewicz et al., 1995). 
 Even though several reports stress the point that cell death or damage might be an 
explanation for bFGF liberation from cells (Hartnett et al., 1999; Rhoads et al., 2000; 
McNeil et al., 1989; Brooks et al., 1991) an early study demonstrated that the 
migration of an isolated single cell expressing bFGF could be inhibited by a bFGF-
neutralizing antibody (Mignatti et al., 1991), indicating a mechanism other than cell 
death or damage leads to bFGF release. This point was further verified by the 
observations that COS-1 cells selectively secreted the 18-kDa isoform of bFGF and 
not the high molecular weight (HMW) isoforms (22, 22.5 and 24 kDa), and that the 
release was dependent upon the α-subunit of the Na+,K+ ATPase (Florkiewicz et al., 
1995; Florkiewicz et al., 1998). These findings strongly suggest that the bFGF export 
process is a controlled and active mechanism, distinct from the classical protein 
secretion. But how is bFGF liberated from the cells? An interesting question, that still is 
unanswered today although numerous studies have tried to find an answer. In the 
following, current concepts on protein secretion in general and unconventional 
protein export in particular will be presented.  
 
Protein secretion 
 
Secretion of proteins via the endoplasmatic reticulum (ER) -Golgi pathway, called 
the classical or the conventional secretory pathway, is understood in great detail. In 
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contrast, even though the phenomenon of non-classical protein secretion (also 
known as un-conventional protein export or ER-Golgi-independent protein secretion) 
was discovered more than 10 years ago, the molecular mechanisms by which the 
proteins are exported from the cell are still not clear.  
 
Classical ER-Golgi dependent protein secretion 
Almost all proteins synthesised in the cell which are secreted from the cell into the 
extracellular space need to pass the endoplasmatic reticulum (ER) and the Golgi 
complex. In mammalian cells, the import of proteins into the lumen of the ER begins 
before the proteins are fully translated; hence, this import is called a co-translated 
process. In this process, in which the protein to be secreted is still attached to its 
ribosome, the protein-ribosome complex will be guided towards the membrane of 
the ER by a signal sequence at the N’-terminal of the protein. A signal-recognition 
particle (SRP) leads the protein to the ER membrane, by binding to the signal 
sequence on the protein (figure 4A). The SRP-ribosome complex binds to a SRP 
receptor, which is an integral protein exposed only to the cytosolic surface of the ER 
membrane. This interaction brings the complex to a protein translocator (called 
Sec61 complex), which is a water-filled pore in the membrane. The SRP and the SRP 
receptor are then released as the growing polypeptide chain is translocated across 
the ER membrane through the translocator (figure 4B). The ribosome binds to the 
translocator by forming a tight seal, insuring that the transferring polypeptide is not 
lost into the cytosol. The signaling sequence in the polypeptide chain binds to a 
specific site inside the pore of the translocator, which thereby opens the pore. This 
means that an ER signaling sequence is recognized twice: first by a SRP in the cytosol 
and second by a binding site in the ER translocator. The N’-terminal signaling 
sequence is removed from the polypeptide chain by a signaling peptidase on the 
luminal side of the ER membrane. However, the signaling sequence remains bound 
to the translocator while the rest of the protein is transferred through the pore of the 
membrane as a large loop. When the C-terminus of the protein has passed through 
the pore, the protein is released into the lumen of the ER and the signaling sequence 
is released into the ER membrane, where it is rapidly degraded (figure 4C).  
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 When the protein is inside the ER it is glycosylated, which is thought to be 
prerequisite for proper folding of the protein. The folding is necessary for a protein to 
leave the ER. The proteins destined for secretion are leaving the ER and enter the 
Golgi apparatus. Proteins coming from the ER enter the cis Golgi network, are then 
undergoing a series of covalent modifications followed by exit from the trans Golgi 
network for their destination. In the trans Golgi network, the proteins are sorted in 
three classes: Those destined for lysosomes, those for immediate delivery to the cell 
surface and those for secretory vesicles. In the last case, the secretory vesicles 
containing the proteins to be secreted are bud of the trans Golgi network and 
transported to the cell membrane with which the vesicles fuse and release their 
proteins by exocytosis. Release of proteins from cells can occur continuously (termed 
constitutive secretion) or the secretory proteins can be stored intracellularly in 
specialized secretory granules for release upon an appropriate stimulus (regulated 
secretion). Reviewed in Alberts et al., 2002c and Alberts et al., 2002b. 
 
  
 
Figure 4: Schematic illustration of the role of the ER signaling sequence in directing secretory proteins 
into the lumen of ER.  In brief, the ER signaling sequence at the NH2 terminal of the growing 
polypeptide binds to the SRP (signaling-recognition particle), which guides the growing polypeptide 
and its ribosome to the membrane of the ER by binding to the SRP-receptor (A). Subsequently, the SRP 
and its receptor are released enabling the ribosome to bind to the protein translocator. The signaling 
sequence binds subsequently on the inside of the translocator whereby it is opened making the way 
for the growing polypeptide to cross the membrane (B). As soon as the C-terminal of the protein 
crosses the membrane, the signaling sequence is cut of by a signal pepridase and the protein is 
released into the lumen of the ER, while the signaling sequence is left in the membrane for rapid 
degradation (C). Modified after Alberts et al., 2002b. 
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Non-classical ER-Golgi independent protein secretion 
Basic FGF is just one protein among a large group of proteins which are secreted 
from the cells where they are synthesised in a non-classical way. The group of 
unconventional secreted proteins includes FGF-1 (aFGF) (Jackson et al., 1995; 
Jackson et al., 1992), interleukin-1β (IL-1β) (Rubartelli et al., 1990; Andrei et al., 1999) 
and galectins (Hughes, 1999) and at least four kinds of mechanistically distinct non-
classical export routes have been suggested (Hughes, 1999; Nickel, 2003) (figure 5), 
which briefly will be reviewed here.  
 Direct translocation from the cytosol to the extracellular space across the plasma 
membrane is one way for proteins to be secreted from cells (Nickel, 2003) (figure 5A). 
Basic FGF and aFGF have been suggested to be secreted in this way (Engling et al., 
2002; Backhaus et al., 2004). 
 Exocytosis is another way by which proteins can be liberated from cells (Nickel, 
2003). In this way proteins are kept in vesicles which are fusing with the cell 
membrane and thereby secrete the protein to the extracellular space (figure 5B). It is 
thought that IL-1β is exported from the cells in this way (Andrei et al., 1999). An ATP-
binding-cassette (ABC)-transporter, ABC1, is a protein which is implicated in the 
transport of proteins from the cytosol to the plasma membrane and it is suggested to 
Figure 5: Schematic 
illustration of potential 
export routes of non-
classical protein secretion. 
Four distinct types are 
shown here: Direct 
translocation across the 
cell membrane (A), 
exocytose, where vesicles 
containing proteins are 
fused with the membrane 
whereby the proteins are 
released (B), membrane 
blebbing, where small 
parts of the membrane 
are bud of enclosing 
proteins (C), and a flip-flop 
mechanism directly 
translocating membrane 
proteins across the 
membrane (D). Modified 
after Nickel, 2003. 
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mediate the translocation of IL-1β from the cytosol to the lumen of the vesicles 
(Hamon et al., 1997).  
 Membrane blebbing is a third non-classical protein secretion pathway (Nickel, 
2003). In this way proteins are accumulated directly at the cytosolic side of the cell 
membrane, followed by formation of membrane-bound vesicles (also called 
exosomes) that pinch off the membrane before the proteins are being released into 
the extracellular space (figure 5C). Members of the galectin protein family are also 
thought to be secreted in this way (Hughes, 1999). 
 A flip-flop mechanism has been suggested for translocation of membrane –
anchored proteins across the plasma membrane (figure 5D). A protein such as the 
cell surface protein called HASPB (hydrophilic acylated surface protein B) is 
proposed to be released in this way (Nickel, 2003). 
 
Stimuli for bFGF secretion 
 
Whereas only little is known about the mechanism behind the release of bFGF from 
the producing cells, different stimuli causing the liberation of the growth factor 
without disrupting the cell membrane have been identified: Estrogen has been 
shown to be able to induce release of bFGF (Albuquerque et al., 1998), presumably 
by cross-talking with TGF-β3 (Chaturvedi & Sarkar, 2004; Hentges & Sarkar, 2001). 
Furthermore, hypoxia (Ishibashi et al., 2001; Ishibashi et al., 1995; Ambalavanan et al., 
1999; Kuwabara et al., 1995) and inflammatory cytokines such as tumor necrosis 
factor-α, interferon-γ, interleukin-1β (Samaniego et al., 1995; Samaniego et al., 1997) 
as well as interferon-α and interleukin-2 when they are administrated in combination 
(Cozzolino et al., 1993) stimulate cells to release bFGF. Additionally, stimuli such as 
nicotine (Cucina et al., 1999b), thrombine (Cucina et al., 1999a; Herbert et al., 1994) 
and elevated hydrostatic pressure (Acevedo et al., 1993) are also influencing the 
release of the growth factor. 
 Interestingly, shear stress has been demonstrated to be a very potent stimulus for 
bFGF release from endothelial cells in vitro (Gloe et al., 2002) as well as in vivo (Lepidi 
et al., 1995). However, the knowledge about how the shear stress as a mechanical 
signal is translated into the biochemical response represented by a release of bFGF is 
only very limited. The study from Gloe et al. (2002) showed that the shear stress 
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induced bFGF release was critical dependent upon integrin αvβ3, indicating that this 
integrin is involved in the mechanotransduction process. It is, however, not clear in 
what way this integrin is contributing to the bFGF release. 
 
Shear stress and signaling transduction 
 
Shear stress is the mechanical force exerted on endothelial cells, which are lining the 
inner surface of the vessels, when blood is flowing in the vessels. An increase in blood 
flow velocity through a vessel, as a result of for example exercise, elevates shear 
stress on the endothelial surface. As an early response to shear stress, the vessels will 
dilate, to be able to deliver more blood to the working muscles in order to meet their 
increased demand of oxygen and nutrients. By chronic shear stress, for example as a 
consequence of training, enlargement of existing vessels, arteriogenesis, as wells as 
formation of new capillaries, angiogenesis, will occur.  
 More than 150 years ago, Virchow observed the ability of the vascular endothelium 
to sense and respond to the flow of blood, referring to the heterogeneous 
morphology of the endothelium along the arterial tree, which correlated with the 
patterns of flow to which the cells were exposed (Resnick et al., 2003). Since then, a 
substantial amount of studies have investigated the response of the endothelium to 
changes in blood flow. The endothelium can react to an acute increase in blood 
Figure 6: Illustration of two signaling transduction models. (A) The shear stress force is sensed by a 
mechanosensor located on the luminal cell surface. This mechanosensor can be a cell surface 
protein or mechanoactivated ion-channels. The signal is subsequently submitted within the cell via 
second messengers. (B) The shear stress force on the luminal surface is recognized by a membrane 
protein, which can transmit the signal by cytoskeletal deformation. The stress stimuli are subsequently 
transmitted to site remote from the origin, where the cytoskeleton is connected to membrane proteins 
(marked in red), such as intracellular junctions (e.g. PECAM), abluminal focal adhesion attachment 
(e.g. integrins) and nuclear membrane. Modified after Davies, 1995. 
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flow by dilatation of arteries through nitric oxide (NO), prostaglandins, and 
hyperpolarizing factors (Frangos et al., 1985; Pohl et al., 1986; Huang et al., 2001), as 
well as to chronic flow alterations by structural remodeling of the artery wall (Langille 
& O'Donnell, 1986). But how does the endothelium sense the shear stress and 
translate it into biochemical responses?  
 It has been suggested that structures on the surface of endothelial cells function as 
a flow sensors (Mazzag et al., 2003). Such sensors are not only located on the luminal 
surface of the endothelium but may also be located at intercellular connections 
(PECAM) or abluminal side (integrins) being activated directly by mechanical 
deformation of the cell or indirectly by altered load of the cytoskeleton (Mazzag et 
al., 2003; Berk et al., 1995; Davies et al., 1997; Davies, 1995) (figure 6). However, a 
substantial amount of evidence points to that integrins are directly involved in the 
signaling transduction in endothelial cells under shear stress (Tzima et al., 2001; 
Pampori et al., 1999; Davies, 1995). This idea is further substantiated by the fact that 
many of the signaling pathways activated by integrin stimulation are also activated 
by shear stress (Shyy & Chien, 2002; Shyy & Chien, 1997). However, the knowledge 
about how integrins directly can be activated during shear stress is still not complete. 
 
Integrins and cell-matrix interaction 
 
Integrins are the sites primary responsible for cell adhesion and are involved in the 
regulation of endothelial cell signaling, morphology, proliferation, migration and 
differentiation (Davies, 1995). They are membrane-associated glycoproteins 
composed of α and β subunits. Each subunit has a large extracellular domain, a 
transmembrane spanning region and a short cytoplasmatic domain. The 
extracellular domain binds directly to the extracellular matrix (ECM) proteins, such as 
vitronectin, fibronectin, laminin and collagen (Shyy & Chien, 2002). The 
cytoplasmatic domain is associated with adapter proteins such as the cytoskeletal 
proteins α-actinin, vinculin, talin, tensin and paxillin, and the signaling molecules focal 
adhesion kinase (FAK), Src family protein tyrosine kinases (PTK’s) and p130Cas 
(termed focal adhesion), all of which are tyrosine phosphorylated by integrin-
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mediated cell adhesion to the ECM (Shyy & Chien, 2002;Shyy & Chien, 1997) (figure 
7).  
 The focal adhesions are perhaps the most intensively studied cytoskeletal-linked 
mechanotransductions sites. The first evidence that integrins are implicated in 
mechanotransduction came from the observation that shear stress applied to the 
luminal surface of endothelial cells resulted in a directional remodeling of the 
abluminal focal adhesion sites (Davies et al., 1994; Davies et al., 1993). As integrins 
bind to the ECM, they become clustered in the plane of the cell membrane and via 
the associated adapter proteins they can initiate signaling transduction (Giancotti & 
Ruoslahti, 1999; Shyy & Chien, 2002). However, even in quiescent cells there is a rapid 
turnover of integrin attachment and detachement (Davies, 1995) and hence, it is not 
fully understood what the signal for integrin activation and subsequently intracellular 
signaling is. However, proteases have been shown to influence integrins positively 
and thereby contribute to their activation (Preston et al., 2002; Geiger et al., 2001; 
Mott & Werb, 2004; Faisal Khan et al., 2002; Koshikawa et al., 2000), but it is still 
unknown whether proteases are able to mediate integrin activation in response to 
shear stress.  
 
 
 
Figure 7: Schematic illustration of the proteins involved in the focal adhesion site. Modified 
after Gloe & Pohl, 2002. 
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Intracellular signaling 
 
As mentioned previously, endothelial cells can respond in an acute and a chronic 
way to enhanced shear stress (Berk et al., 1995; Tseng et al., 1995). It has been 
suggested that the acute and transient response is mediated by a calcium 
dependent pathway, whereas the slow and sustained signal is mediated by a 
calcium-independent pathway. The calcium dependent pathway involves 
activation of phospholipase C, hydrolysis of phosphatidylionsitol 4,5-biphosphate 
(PIP2), increase in intracellular calcium and formation of the calcium-calmodulin 
complex and stimulation of PKC, leading to activation of nitric oxide synthase (NOS) 
and ion transport (figure 8B). In contrast, the calcium-independent pathway involves 
activation of a small GTP-binding protein and stimulation of calcium-independent 
PKC and MAP kinases, leading to a sustained activation of NOS and changes in cell 
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Figure 8: Schematic diagram of the shear stress-induced pathways. (A) The calcium-
independent pathway involving integrin-mediated MAP kinase activation. The p38 MAPK 
pathway can induce heat shock protein 27 (HSP27) phosphorylation via MK (MAPKAP kinase) 
2/3 and PRAK (MAPKAP kinase 5. ERK1/2 (p42/44 MAP kinase) can also activate MK2 and PRAK 
and thereby presumably phosphorylate HSP27 (see text for more information). The thin black 
dotted line indicates nucleus. (B) The calcium-dependent pathway activated by shear stress. 
Modified after (Berk et al., 1995) and Tseng et al., 1995. 
 
Introduction 
 26 
morphology and gene expression (Berk et al., 1995; Tseng et al., 1995). 
 For a long time it has been known that shear stress can activate the extracellular 
signaling-regulated kinase (ERK1/2) pathway as well as the c-Jun NH2-terminal 
protein kinase (JNK) pathway (Azuma et al., 2000; Takahashi & Berk, 1996; Minden et 
al., 1995; Coso et al., 1995; Tseng et al., 1995; Jo et al., 1997). The small GTPases 
p21Ras, Rac1 and Cdc42 are activated during shear stress in an integrin-dependent 
manner initiating the JNK pathway leading to c-Jun transcription (Coso et al., 1995; 
Minden et al., 1995; Tzima et al., 2003; Tzima et al., 2002). On the other hand, the 
shear stress induced integrin-dependent Ras and Raf activation seems to be 
implicated in the activation of the ERK1/2 pathway (Shyy & Chien, 2002; Li et al., 
1999; Jo et al., 1997) (figure 8A). Recently, Azuma et. al (2001) demonstrated that 
shear stress not only induces activation of ERK1/2 and JNK but also the p38 MAPK-
MAPKAPK-II pathway resulting in phosphorylation of heat shock protein 27 (HSP27) 
(figure 8A), a pathway which has been implicated in cell shape changes and 
migration (Piotrowicz et al., 1998; Hedges et al., 1999; Rousseau et al., 1997). Since 
shear stress is able to induce release of bFGF from cells, as mentioned earlier, it may 
be hypothesized that the phosphorylation of HSP27 plays a role in the release of 
bFGF during shear stress. 
 
The p38 MAPK pathway and HSP27 phosphorylation 
 
Like the other MAP kinases, p38 MAP kinase is predominantly localized in the 
cytoplasm (Seternes et al., 2002). However, upon environmental or cellular stress, p38 
MAPK is activated by phosphorylation, which leads to a translocation of the p38 
MAPK to the nucleus (Chen et al., 1992). In vitro as well as in vivo, the p38 is the 
activator for MAPKAP kinase-2 (MK2) (Rouse et al., 1994), MAPKAP kinase-3 (MK3) 
(McLaughlin et al., 1996), and MAPKAP kinase-5 (PRAK (p38 regulated and –
activated protein kinase)) (Ni et al., 1998; New et al., 1998), which in the inactivated 
forms are localized in the nucleus (Seternes et al., 2002; Lenormand et al., 1993) 
(figure 8A). Following phosphorylation of MAPKAP kinases, nuclear p38 MAPK is 
exported to the cytoplasm in a complex with the given MAPKAP kinase (Engel et al., 
1998; Ben Levy et al., 1998; Seternes et al., 2002). In the cytoplasm, the MAPKAP 
kinase 2/3 and PRAK phosphorylate HSP27 (Stokoe et al., 1992b; Clifton et al., 1996; Ni 
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et al., 1998; New et al., 1998). In vitro, the p42/44 MAPK has been shown also to be 
able to activate MAPKAP kinase-2 (Clifton et al., 1996; Stokoe et al., 1992a) and 
thereby HSP27 (Huot et al., 1995). However, other studies could not show the HSP27 
phosphorylation via the p42/44 pathway (Guay et al., 1997; Rouse et al., 1994; 
Gaitanaki et al., 2003). Moreover, p42/44 MAPK is also able to activate PRAK and by 
that phosphorylate HSP27 (Ni et al., 1998). 
 HSP27 is a stable protein present at low levels in nearly all cells and tissues, and is a 
member of a large family of chaperones, which assists in the folding of many 
different proteins (Alberts et al., 2002a). In unstressed cells, HSP27 is found in the 
cytosol predominantly as a large oligomeric unit of 500 – 800 kDa, usually consistent 
of six tetrameric complexes of the protein (Arrigo & Welch, 1987; Arrigo et al., 1988). 
An enhanced expression and phosphorylation of HSP27 is seen as a response to 
estrogen (Piotrowicz et al., 1995), different forms of stress, such as heat shock (Rouse 
et al., 1994; Landry et al., 1992; Arrigo et al., 1988), oxidative stress (Barchowsky et al., 
1994) as well as shear stress (Piotrowicz et al., 1997; Azuma et al., 2001; Li et al., 1996), 
and cytokines such as interleukin 1 (IL-1) (Freshney et al., 1994; Guesdon et al., 1993), 
TNF (Landry et al., 1992; Guesdon et al., 1993), thrombin and histamine (Levin & 
Santell, 1991), many of which also leads to an active release of bFGF, as mentioned 
earlier.  
 Phosphorylation occurs on three different serine residues, Ser-15, Ser-78 and Ser-82 
(Landry et al., 1992) resulting in a re-distribution of the large oligomer into smaller 
tetrameric units (Kato et al., 1994) and translocation to the nucleus (Arrigo & Welch, 
1987; Arrigo et al., 1988). In vitro, HSP27 behaves as an actin-capping protein, which 
in the non-phosphorylated form inhibits actin polymerization, whereas when HSP27 is 
phosphorylated it seems to leave the actin, allowing the actin to polymerize (Lavoie 
et al., 1995; Guay et al., 1997; Benndorf et al., 1994; Miron et al., 1991; Miron et al., 
1988). The dynamics of the microfilament polymerization is important for 
lamellopodia formation and morphology observed during shear stress, and thus for 
the motility of endothelial cells (Piotrowicz et al., 1998) and smooth muscle cells 
(Hedges et al., 1999). Furthermore, transfection of bovine aortic endothelial cells 
(BAEC) with human HSP27 resulted in a 2-3 fold enhancement cellular growth 
(Piotrowicz et al., 1995) and additionally it has been demonstrated that 
phosphorylation of HSP27 is required for cell migration (Piotrowicz et al., 1998), two 
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processes which are also mediated by bFGF (Nugent & Iozzo, 2000). Moreover, HSP27 
has interestingly been shown to co-precipitate with bFGF and has therefore been 
proposed to facilitate the release of the growth factor (Piotrowicz et al., 1997). 
However, it is not known how HSP27 can facilitates the bFGF release, but it is 
suggested that the function of HSP27 is activated by phosphorylation (Guay et al., 
1997), giving rise to the hypothesis that activated HSP27 could play an important role 
in the release of bFGF during shear stess. 
 
Hypothesis 
 
In the view of the fact that shear stress induces an integrin-dependent release of 
bFGF from endothelial cells, it is in this thesis hypothesized that the shear stress 
induced bFGF liberation from endothelial cells is controlled by cell-matrix interactions 
and since proteases are able to remodel the extracellular matrix it is further 
hypothesized that proteases are required for the activation of integrin αvβ3 and 
subsequently initiation of the intracellular signaling cascade resulting in the bFGF 
release. 
 Moreover, since shear stress induces HSP27 phosphorylation, it is hypothesized that 
HSP27 in the phosphorylated form acts as a carrier for bFGF upon its release through 
the cell membrane. 
 
Aims 
 
In view of the importance of bFGF in biological systems it seems essential to gain 
more information about its release mechanism. Whereas shear stress is a known 
stimulus for bFGF release from endothelial cells the chain of molecular mechanisms 
by which the shear stress forces are translated finally into release of bFGF still needs 
to be elucidated. As pointed out in the introduction, numbers of studies have looked 
at integrins as possible mechanotransducers, and recently, proteases have been 
suggested as potential integrin activators. Hence, the first aim of the present study is 
to clarify the role of proteases in the mechanotransduction of shear stress forces into 
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the release of bFGF from endothelial cells. A second aim of this study is to elucidate 
the role of HSP27 in facilitating the release of bFGF. 
In detail, the following questions were aimed to be answered in this context: 
 
1.  Mechanotransduction of shear stress into bFGF release: 
 Do cells have to be attached to the extracellular matrix in order to release 
bFGF in respond to shear stress? 
 Do proteases play a role in the shear stress-induced bFGF release by 
remodeling the extracellular matrix? 
• Is protease activity increased during shear stress? 
• What kind of protease could be involved? 
• Can proteases, when administrated alone, induce bFGF release in 
static cells? 
• Do protease treatment and shear stress induce similar pathways in 
endothelial cells? 
 How can the integrin αvβ3 contribute to the bFGF release? 
 
2.  bFGF release: 
 Which intracellular signaling cascade is involved 
 Does HSP27 phosphorylation play a role?  
 Are HSP27 and bFGF interacting? 
 How is bFGF released? 
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Materials 
 
All cell culture reagents were obtained in highest purity from Sigma (Taufkirchen, 
Germany), except from fetal calf serum which was purchased from Biomol 
(Hamburg, Germany). The L-15 medium used in shear stress experiments performed 
with the parallel plate system is also obtained from Sigma (Taufkirchen, Germany). All 
the membranes used for sterilization was purchased from MembraPure GmbH 
(Bodenheim, Germany).  Laminin type I (mouse) used for coating the culture dishes 
was from Harbo Bio-Products (Norwood, MA, USA) and the collagen type I was 
purchased from Genaxxon bioscience (Stafflangen, Germany). Porcine pancreatic 
elastase utilized for treating static cells with elastase was obtained from SERVA 
electrophoresis (Heidelberg, Germany) and the elastase specific substrate (MeOSuc-
Ala-Ala-Pro-Val-pNA) from Bachem (Weil am Rhein, Germany). The bFGF ELISA kit 
was obtained from R&D systems (Wiesbaden-Nordenstadt, Germany). The enhanced 
chemoluminescence protein detection kit was from Applichem (Darmstadt, 
Germany) and the BCA protein assay kit was purchased from Pierce (Bonn, 
Germany). 3,3’,5,5’ tetramethylbenzidine (TMB) was obtained from Sigma 
(Taufkirchen, Germany). The dialyzing tubes were from MembraPure GmbH 
(Bodenheim, Germany) and the ampholytes pH 3-10 as well as pH 5-8 was 
purchased from Fluka (Taufkirchen, Germany). The protein A- micro beads and the 
MACS columns utilized for immuno-precipitation were obtained from Miltenyi Biotec. 
(Auburn, CA). The CellWASH and the propidium iodid used in FACS analysis were 
from BD Biosciences (Erembodegem, Belgium). The polyacrylamid:bis solution for 
making SDS-PAGE was obtained from Genaxxon bioscience (Stafflangen, Germany). 
The nitrocellulose membrane used for Western blot was from PeqLab (Erlangen, 
Germany). Formaldehyde used for fixation of cells was obtained from Sigma 
(Taufkirchen, Germany). Silicone solution was obtained from SERVA electrophoresis 
(Heidelberg, Germany). 
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Media 
 
DMEM (10%) 
Dulbecco’s modified Eagle’s medium 
(DMEM) (Dulbecco & Freeman, 1959) 
445 ml 
Penicillin (10000 U) / streptomycin (10 mg) 2 ml 
L-Glutamine (200 nM) 5 ml 
Fetal calf serum (10%) 50 ml 
pH 7.4  
 
DMEM (1%) 
Dulbecco’s modified Eagle’s medium 
(DMEM) (Dulbecco & Freeman, 1959) 
450 ml 
Penicillin / streptomycin 3 ml 
Glutamine (200 nM) 5 ml 
Fetal calf serum (1%) 4.5 ml 
pH 7.4  
 
Leibovitz L-15 medium 
Leibovitz L-15 medium (LEIBOVITZ, 1963) 445 ml 
Penicillin (10000 U) / streptomycin (10 mg) 2 ml 
L-Glutamine (200 nM) 5 ml 
Fetal calf serum (1%) 4.5 ml 
pH 7.4  
 
Sterilization of all the media was done by passing the media through two filters. First a 
Glasfaser filter (C5) with a pore size of 0.45 µm and second a Memfil CA with a pore 
size of 0.2 µm. 
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Buffers and solutions 
 
Anolyte 
Phosphoric acid (85%) 0.68 ml 
Distilled H2O 1000 ml 
 
Blocking buffers 
 A-blocking buffer (3% milk) 
 3% non-fat dry milk in TBST 
 
 B-blocking buffer (5% BSA) 
 5% BSA in TBST 
 
 C-blocking buffer (5% BSA) 
 5% BSA in PBS(-) 
 
 D-blocking buffer (1% BSA) 
 1% BSA in PBS(-) 
 
 E-blocking buffer (10% FCS) 
 10% FCS in PBS/Triton 
 
 F-blocking buffer (10% FCS) 
 10% FCS in PBS(-) 
 
Catholyte 
NaOH 2.4 g 
Distilled H2O 600 ml 
Freshly made and degassed immediately prior to use 
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Citrate buffer (15 mM) 
135 mM KCl 10.06 g 
15 mM NaCitrate 4.4 g 
H2O ad 1000 ml 
 
Collagenase solution (170 U/ml) 
Collagenase type I (1700 U/mg) 1 g 
PBS(+) 1000 ml 
The collagase solution was passed through the filter Membrex 25 CA with a pore size 
of 0.2 µm in order to sterilize the solution. 
 
Elastase (0.5 U/ml) 
Porcine pancreatic elastase (130 U/ml) 7.6 µl 
DMEM (1%) 2 ml 
 
Formaldehyde 
 
 3.7% formaldehyde 
 3.7% formaldehyde in PBS(-) 
 
 4% formaldehyde 
 4% formaldehyde in PBS(-) 
 
 10% formaldehyde 
 10% formaldehyde in PBS(-) 
 
H2O2 (0.6%) 
0.6% H2O2 (30% solution) in PBS/Triton. 
Always freshly made prior to use. 
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IEF-gel (13.5%): 
Urea 16.3 g 
10% Triton-X-100 6 ml 
Distilled H2O  6 ml 
Acrylamide/Bisacrylamide 30%/0.8% (w/v) 4.05 ml 
Ampholyte pH 5-8 1.2 ml 
Ampholyte pH 3-10 0.3 ml 
APS 0.06 ml 
TEMED 0.03 ml 
 
IEF solubilization: 
Urea 5.7 g 
10% triton-X-100 2 ml 
Ampholyte pH 3-10 0.2 ml 
Mercaptoethanol 0.5 ml 
H2O ad 10 ml 
 
IEF-washing buffer: 
Tris-HCl [pH 8.0] 1.2 g 
Methanol 1000 ml 
SDS 20 g 
H2O ad 2000 ml 
 
Laminin (10 µg/ml) 
Laminin type I (2.5 mg/ml) 4 ml 
PBS(+) 996 ml 
The laminin solution was passed through the filter Membrex 25 CA with a pore size of 
0.2 µm in order to sterilize the solution. 
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Lysis buffer (w. Triton-X-100): 
KH2PO4  
EDTA 
Pefablock 
Leupeptin  
Pepstatin 
NaF  
Na4-pyrophosphate  
Na3VO4 
Triton-X-100  
pH = 7.4 
20 mM  
1 mM  
1 mM  
1 µM  
1 µM  
50 mM  
40 mM  
2 mM  
1 % 
 
 
Lysis buffer (w/o Triton-X-100): 
KH2PO4  
EDTA 
Pefablock 
Leupeptin  
Pepstatin 
NaF  
Na4-pyrophosphate  
Na3VO4 
pH = 7.4 
20 mM  
1 mM  
1 mM  
1 µM  
1 µM  
50 mM  
40 mM  
2 mM  
 
 
Overlay buffer: 
IEF solubilization buffer diluted 1:3 with water with Bromophenol blue 
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Phosphate buffered saline (PBS) 
 PBS (-):     PBS(+): 
   NaCl 8.00 g  NaCl 0.80 g 
   KCl 0.20 g  KCl 0.20 g 
   Na2HPO4x 2H2O 1.42 g  Na2HPO4 1.15 g 
   KH2PO4 0.20 g  KH2PO4 0.20 g 
   H2O               ad 1000 ml  MgCl2  0.04 g 
   pH 7.4   H2O           ad 1000 ml 
 
PBS(-) was autoclaved and PBS(+) was passed through the filter Memfil CME with a 
pore size of 0.2 µm in order to sterilize the solutions. 
 
PBS/Triton 
PBS(-) containing 0.1% Triton-X-100  
 
Running buffer (5x): 
Tris Base 75 g 
Glycine 360 g 
SDS 25 g 
H2O ad 5 l 
 
Sample / loading buffer (4x): 
Tris-HCl [pH 6.8] 0.25 M 
SDS 8 % 
Glycerine  40 % 
Bromphenolblue 0.02 % 
Mercaptoethanol 400 mM 
 
 
 
 
 
 
Materials and methods 
 38 
SDS-PAGE: 
 Separations gel: 
 10% 12% 
   H2O 20.00 ml 16.7 ml 
   Tris (1.5 M) [pH 8.8] 12.50 ml 12.5 ml 
   SDS 10% (w/v)   0.50 ml   0.5 ml 
   Acrylamide/Bisacrylamide 30%/0.8% (w/v) 16.60 ml 20.0 ml 
   Ammoniumpersulfate (APS) 10% (w/v)   0.25 ml   0.25 ml 
   TEMED   0.025 ml   0.025 ml 
 Stacking gel (4%): 
   H2O 6.00 ml 
   Tris (0.5 M) [pH 8.8] 2.50 ml 
   SDS 10% (w/v) 0.10 ml 
   Acrylamide/Bisacrylamide 30%/0.8% (w/v) 1.30 ml 
   Ammoniumpersulfate (APS) 10% (w/v)  0.05 ml 
   TEMED 0.01 ml 
 
Sodium orthovanadate (Na3VO4) (100mM) 
Na3VO4 183,9 mg 
dH2O 10 ml 
 
The sodium orthovanadate should be activated for maximal inhibition of tyrosine 
phosphotases. By the following activations procedure the vanadate was 
depolymerized: 
1. The pH of Na3VO4 solution was adjusted to pH 10.0. At this pH the solution is 
yellow 
2. The solution was boiled until it turned colorless (approximately 10 min) 
3. It was cooled down to room temperature 
4. The pH was readjusted to pH 10.0 and the steps 2 and 3 was repeated until the 
solution remained colorless and the Ph stabilized at 10.0 
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TBST: 
Tris-HCl [pH 7.4] 50 mM 
NaCl 150 mM 
Tween 20 0.3 % 
 
Transfer buffer: 
Clycine 39 mM 
Tris Base 48 mM 
SDS 0.037 % 
MeOH 10 % 
 
Antibodies 
Primary antibodies 
The primary antibodies used in the study are listed in table 2.  
 
Table 2: Primary antibodies. PC = Polyclonal antibody; MC = Monoclonal antibody; FA = 
Fractionated antiserum. 
Antibody Raised in Company Place 
Product
# 
Application 
Conc./ 
dilution  
Western Blot 1:5000 
Immuno-
staining 
1:200 Rabbit 
(PC) 
Stressgen Hamburg, DE 
SPA-
803 
Modified 
ELISA 
20 
µg/ml 
Anti-HSP27 
Mouse 
(MC) 
Acris 
Bad Neuheim, 
DE 
BM152 
Isoelectric 
focusing 
1:1000 
Anti-phospho 
HSP27 (Ser-78) 
Mouse 
(MC) 
Upstate Hamburg, DE 05-645 
Modified 
ELISA 
20 
µg/ml 
Anti-phospho 
HSP27 (Ser-82) 
Rabbit 
(PC) 
Cell Signaling Frankfurt, DE 2401 PACE 1:200 
FACS 1:200 Rabbit 
(FA) 
Sigma 
Taufkirchen, 
DE 
F3393 
FACE 1:400 
Anti-bFGF 
Mouse 
(MC) 
R&D systems 
Wiesbaden, 
DE 
CONJU
GATE08 
Modified 
ELISA 
50 µl 
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Anti-p38 
Rabbit 
(PC) 
Stressgen Hamburg, DE 
KAS-
MA009 
Western  Blot 1:5000 
Anti-phospho 
p38 
(Thr180/Tyr182) 
Mouse 
(MC) 
Cell Signaling Hamburg, DE 28B10 Western  Blot 1:2000 
Anti-phospho 
p42/44 
(Thr202/Tyr204) 
Mouse 
(MC) 
Cell Signaling Hamburg, DE 9106S Western  Blot 1:500 
Anti-phospho 
serine 
Rabbit 
(PC) 
Abcam Cambridge,UK Ab9332 
Immuno-
precipitation 
0.25µg
/100µg 
protein 
Anti-actin Goat Santa Cruz 
Heidelberg, 
DE 
I-19 Western blot 1:500 
Anti-PECAM Goat Santa Cruz 
Heidelberg, 
DE 
M-20 Western blot 1:500 
 
Secondary antibodies 
Table 3 gives an overview of the horseradish peroxidase (HRP)-conjugated 
secondary antibodies used in this study. 
Table 3: HRP-conjugated secondary antibodies 
Antibody Raised in Company Place Product # Application Dilution 
Anti- 
mouse 
Goat Calbiochem 
Schwalbach, 
DE 
DC-08L Western blot 1:25000 
Anti-rabbit Goat Calbiochem 
Schwalbach, 
DE 
DC-03L 
Western blot 
PACE 
FACE 
Self-made ELISA 
1:25000 
1:400 
1:800 
1:400 
Anti-goat Rabbit Calbiochem 
Schwalbach, 
DE 
DC-03L Western blot 1:10000 
 
In table 4 are shown the fluoreceine-isothiocyanate (FITC)-labled secondary 
antibodies which were utilized for immunohisto-chemistry and FACS analysis. 
 
Table 4: Fluorescent labeled secondary antibody 
Antibody Raised in Company Place Product # Application Dilution 
Anti-rabbit Goat Invitrogen Karlsruhe, DE 65-6111 Immuno-staining 1:400 
Anti-rabbit Chicken Invitrogen Karlsruhe, DE A-21441 FACS 1:400 
 
Materials and methods 
 41 
Inhibitors 
 
A list of inhibitors used in the study is found in table 5.  
Table 5: Overview of used inhibitors. 
Inhibitor Inhibitor of Company Place 
Product 
# 
Experiment used in conc. 
Aprotinin 
Unspecific 
serine 
proteases 
Applichem 
Unter-
föhring, DE 
A2132 
Shear stress for 
bFGF release 
200 
U/ml 
Abciximab 
Integrin 
αvβ3 
Lilly 
Bad 
Homburg, 
DE 
VL7140
001 
Elastase treatment 
for bFGF release, 
FACS, Phospho-
HSP27  
0.5 
µg/ml 
SB202190 p38 MAPK Upstate 
Hamburg, 
DE 
19-134 
Elastase treatment 
for Phospho-HSP27 
1 µM 
Elastatinal Elastase SERVA 
Heidelberg, 
DE 
51798-
45-9 
Elastase treatment 
for FACS 
2 µM 
GF109203X 
PKC 
inhibitor 
Biosource 
Solingen, 
DE 
PHZ108
3 
FACS 8 µM 
 
Cell culture 
 
Medium: 
 DMEM (10%) 
 
Buffers and solutions: 
 PBS(+) 
 PBS(-) 
 Collagenase solution 
 
Cell isolation 
 
Porcine aortic endothelial cells (PAEC) were used throughout all the experiments. The 
isolation of the PAEC was done as described previously by Gloe et. al (1999). In short, 
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fresh aorta were obtained from the local slaughterhouse and kept in sterile in PBS(+) 
until the final preparation. Fat and connecting tissue was trimmed from the aorta 
before it was cut longitudinally thereby exposing the luminal surface. After washing in 
PBS(-), the vessels were placed into a frame with the luminal side facing up. 
Thereafter, they were incubated in a sterile collagenase solution for 20 min at 37 °C in 
a humidified incubator. Finally, culture medium was applied to wash off the 
endothelial cells, whereupon they were cultivated in standard plastic culture dishes 
in DMEM (10%) at 37°C and gassed with air enriched with 5 % CO2.  
 
Shear stress 
 
Passages 2-3 of PAEC were used for application of shear stress either by the cone-
and-plate technique or by the parallel plate system. The two systems are previously 
described by Gloe et al. (1999) and Koslow et al. (1986) and Frangos et al. (1987), 
respectively. The different systems were used for various reasons. The cone-and-plate 
apparatus needs less medium (7 ml) than the parallel plate system (50 ml), making 
the cone-and-plate system an advantage when inhibitors are administrated during 
the shear stress because less of the expensive inhibitors needs to be added. On the 
other hand, the cone-and-plate apparatus cannot be utilized for immuno-
histochemistry experiments, since it is equipped with a glass plate of 10 cm in 
diameter which is too thick for the proper application of high magnification 
microscope lenses. Instead, the smaller glass plates of the parallel plate system (4.5 
cm diameter) are much thinner and are therefore more suitable for microscopic 
analysis of cells grown on them. 
 
Cone-and-plate shear apparatus 
 
Media: 
 DMEM (10%) 
 DMEM (1%) 
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Buffer and solutions: 
 Laminin type I 
 
Inhibitor: 
 Aprotinin 
 
PAECs were seeded onto glass plates with a diameter of 10 cm pre-coated with 
laminin type I. The seeding of the cells onto a glass plate was done since plastic 
culture dishes were not suitable for shear stress experiment because they exhibited a 
high variability in the bottom thickness and were not perfectly planar.  
 After plating the endothelial cells onto the glass plate they were left in DMEM (10 
%) until they were confluent (approximately 1-2 days). The confluent glass plates 
Figure 9: Cone-and-plate apparatus. Cells were plated onto a glass plate pre-coated with laminin 
I. When the cells were confluent, the glass plate was inserted into the lower chamber (dashed line). 
The upper part (the rotating cone (solid line)) was lowered close to the cells. By rotating, the 
medium (7 ml DMEM (1% ) was set in motion creating a laminar shear stress on the cells. 
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were transferred into the cone-and-plate apparatus (see fig. 9), 7 ml DMEM (1 %) 
was added and a laminar shear stress of 16 dyn/cm2 was applied to the endothelial 
cells for 2 hours at 37 °C.  
 In some experiments the unspecific serine protease inhibitor, aprotinin, was added 
to the medium during shear stress exposure. After shear stress, the supernatant was 
collected for measurement of bFGF release and elastase-like activity (see later 
description). The cells were lysed as described later. 
 
Parallel-plate shear apparatus 
 
Media: 
 DMEM (10%) 
 Leibovitz L-15 (1%) 
 
Buffers and solutions: 
 Laminin type I 
 3.7% formaldehyde 
 
The parallel plate system was used in the case where the shear stress exposed cells 
should be analyzed by immuno-histochemistry. PAEC were seeded onto glass plates 
with a diameter of 4.5 cm pre-coated with laminin type I. The cells were allowed to 
adhere to the glass plate in DMEM (10 %). When the cells were confluent after 
approximately 1-2 days, the glass plate were placed in a gap of the lower plate of 
the parallel plate chamber and the upper plate of the camber was placed on top, 
the distance between both plates being determined by a Teflon gasket (fig. 10). The 
camber was placed on a heating block insuring a constant temperature of 37°C for 
the cells. Leibovitz L-15 medium (1 %) was allowed to flow over the cells creating a 
laminar flow. Leibovitz L-15 medium was used because the shear stress experiment 
was preformed outside a CO2 incubator, i.e. in a carbon dioxide free environment. 
The Leibovitz L-15 medium is buffered by salts, free amino acids and galactose, 
which is contained in the medium and help to maintain physiological pH control. 
A 
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In this shear stress system the shear rates over the glass plate with the cells is linear 
with flow rate. The velocity profile for laminar flow between parallel plates is given by 
the equation (Frangos et al., 1987) 
 
2
6
bh
Qµ
τ =  
 
where Q is the flow rate (cm3/s); µ is the viscosity (ca. 0.01 dyn s/cm2); h is the 
channel height (12 mm); b is the slit width (56 mm); and τ is the shear stress 
(dyn/cm2). 
Figure 10: Parallel-plate system. A. The whole setup with the chamber containing the cells in 
the middle and the pump to the right which pumps the medium through the system. B. The 
chamber containing the cells between the upper and the lower plate. The medium is 
pumped from left to right passing the cells exposing them to a laminar shear stress. 
Flow in Flow out 
Cells 
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 Since the chamber size is given, the only variably in our system is the flow rate (Q). 
At the maximum flow rate for our system the laminar flow was calculated to be 12 
dyn/cm2.  
After 2 hours of shear stress exposure of the cells the glass plate containing the cells 
was quickly taken out of the chamber and fixed in 3.7% formaldehyde overnight at 
4°C. The following day, the cells were stained for immuno-histochemistry (see section 
about immuno-histochemistry). 
 
Elastase treatment 
 
Medium: 
 DMEM (1%) 
 
Buffers and solutions: 
 Elastase (0.5 U/ml) 
 
Inhibitors: 
 Elastatinal (2 µM) 
 Abxicimab (0.5 µg/ml) 
 SB202190 (1µM) 
 
Passage 2-3 of PAEC was used for elastase treatment. The experiments were 
performed on static cells to which no shear stress was applied. For the acute 
experiment, the DMEM (10%) was exchanged for DMEM (1%).  
 To show that the exogenous elastase was functioning, control experiments were 
performed, where a specific substrate for elastase (MeOSuc-Ala-Ala-Pro-Val-pNA) in 
DMEM (1%) was subjected to increasing concentrations of elastase. In parallel, the 
substrate was incubated with elastase in combination with an elastase specific 
inhibitor, Elastatinal. Elastase, by cleaving the substrate, induced a change in the 
absorbance of the reaction solution, which was quantified in a spectrophotometer 
at a wave length of 450 nm. 
B 
 
Materials and methods 
 47 
 In a first series of experiments, different concentrations of elastase were applied to 
the static endothelial cells (0; 0.1; 0.3; 0.5; 1.0 or 2.0 U/ml) for 2 hours at 37 °C. In all 
the following experiment an elastase concentration of 0.5 U/ml was used.  
 In further experiments, one of the following inhibitors or antibodies were added to 
the medium 1 hour prior to the beginning of the elastase treatment: Abciximab, 
which is an inhibitory antibody for GB IIbIIIa on plateletes and for the integrin αvβ3 on 
endothelial cells, an antibody against CD49f (integrin alpha 6) (1.0 µg/ml), an 
unspecific IgG (1.0 µg/ml) and the drug SB202190, which is an inhibitor of p38 MAP 
kinase. 
 
ELISA for bFGF 
 
Reagents: 
 bFGF ELISA kit 
 
The bFGF release was assessed by measuring the concentration of bFGF in the 
conditioned media from non-treated and treated cells. An ELISA kit was utilized and 
the protocol from the manufacturer was strictly followed. Briefly, 100 µl medium from 
control and treated cells was added to the ELISA wells together with a blocking 
agent and incubated for 2 hours at room temperature (RT). After washing 4 times 
with the washing buffer the wells were incubated with 200 µl bFGF conjugate for 2 
hours at RT followed by a washing step. Subsequently, the substrate solution was 
added to the wells and after incubation for 30 min at RT, a stop solution was applied. 
The color reaction was measured using a spectrophotometer at 450 nm and at 620 
nm. From the OD obtained the concentration in pg/ml could be calculated with the 
help of the standard curve. 
 
Measurement of elastase activity 
 
The specific substrate for elastase (MeOSuc-Ala-Ala-Pro-Val-pNA) was added to the 
conditioned medium from either static control cells or from shear stress exposed cells 
(16 dyn/cm2, 2 hours). The cleavage of the substrate by elastase created a yellow 
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reaction solution which was measured at 450 nm. A standard curve was performed 
to convert the measured OD’s into a concentration (mU/ml). 
 
Western blots 
 
Western blotting was used for determining translocation of HSP27 and 
phosphorylation of HSP27, p38 and p42/44 MAP kinases.  
 
Reagents: 
 BCA protein assay kit 
 Enhanced chemoluminescence protein detection kit 
 
Buffers and solutions: 
 PBS(-) 
 SDS-PAGE 
 Lysis buffer 
 Loading / sample buffer 
 Running buffer  
 Transfer buffer 
 TBST (washing buffer) 
 Na3VO4 
 A- and B-blocking buffer 
 
Antibodies: 
 Anti-phospho-p38 MAP kinase antibody 
 Anti-p38 MAP kinase antibody 
 Anti-phospho-p42/44 MAP kinase antibody 
 Anti-Actin 
 HRP-conjugated anti-mouse antibody 
 HRP-conjugated anti-rabbit antibody 
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Cell lysing  
 
Cells exposed to shear stress or treated with elastase and their respective non-
treated control cells, were washed with ice cold PBS(-) and lysed in lysis buffer. The 
cell were left on ice for 10 min to ensure proper cell lysing and the lysates were 
subsequently scraped together with a rubber policeman, passed through a 24G 
needle for three times and centrifuged for 10 min at 10,000 g at 4°C. The 
supernatants were used for further analyzing.  
 
Protein measurement  
 
Measurement of protein concentration was done by a BCA (bicinchoninic Acid) 
protein assay. The principle of this assay is similar to the Lowry procedure (Lowry et al., 
1951), in that a protein-cupper (Cu2+) complex in alkaline conditions is formed. The 
Cu2+ is reduced to Cu1+ by BCA in this assay and folin in the case of the Lowry 
procedure. The amount of reduction is proportional to the protein content. BCA 
forms a purple-blue complex with Cu1+, which was measured in a 
spectrophotometer at a wave length of 550 nm. The protein concentration was 
calculated from a standard curve generated with bovine serum albumin (BSA).  
 
 
SDS-PAGE and protein transfer 
 
Aliquots of the protein preparations (30 µg total proteins) were boiled for 5 min 
(100°C) and spinned donw before they were separated on a 10 or 12% SDS-PAGE. 
After separation of the proteins they were transferred to a nitrocellulose membrane, 
based on the design of (Towbin et al., 1979), by semi-dry transfer technique. In this 
case a sandwich was made of 2-3 filterpapers soaked in transfer buffer, nitrocellulose 
membrane, gel and again 2-3 fitlerpapers. The proteins were blottet 1 hour at 0.8 mA 
/ cm2. 
 After the proteins were blottet onto the membrane, it was blocked with blocking 
buffer either with milk in cases where no phospho-specific antibodies were used or 
 
Materials and methods 
 50 
BSA if phospho-specific antibodies were utilized, followed by incubation with the 
primary antibody (see table 2) in A- and B-blocking buffer, respetively, either for 2 
hours at 37°C or overnight at 4°C. Unspecific bound antibody was washed off by TBST 
(3 x 10 min). The bound primary antibodies were detected by using HRP-conjugated 
anti-rabbit, anti-mouse or anti-goat IgG diluted in milk or BSA blocking buffer (see 
table 3) for 1 hour at RT. The bound secondary antibodies were viewed by using an 
enhanced chemoluminescence protein detection kit and x-ray films (Kodak). The 
detected bands were recorded and quantified with a videodensitometric system 
from Bio-Rad (München, Germany). 
 
Immunoblot for phospho-p38 and phospho-p42/44 
 
Activation of p38- and p42/44 MAP kinase was investigated by determining 
phosphorylation of p38 and p42/44 by Western blotting using phospho-specific 
antibodies. PAEC were either kept as non-treated control cells or treated with 
elastase. In some experiments the elastase treatment was done in addition with 
Abciximab, as described previously. 20 min prior to the elastase treatment, 100 µM 
Na3VO4 was added to the cells. Na3VO4 is an inhibitor of protein tyrosine 
phosphotases and was used to reduce the dephosphorylation of p38 and p42/44 
during elastase treatment. After lysing the cells, the proteins were separated on a 
10% SDS-PAGE. After blocking, the membranes with the transferred proteins were first 
probed with either a phospho-specific anti-p38 antibody or a phospho-specific anti-
p42/44 antibody. To ensure equal loading, the membranes were reprobed with an 
anti-p38 antibody or an anti-actin antibody (see table 2), respectively. The mean 
phosphorylation of p38 (expressed as the ration between phospho-p38 and p38) or 
p42/44 (expressed as the ration between phospho-p42/44 and actin in control cells 
was set to 100% and all other treatment conditions were compared to this group. 
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HSP27 translocation assay 
 
Buffers and solutions: 
 PBS(-) 
 12% SDS-PAGE 
 Lysis buffer (w/o Triton-X-100) 
 Lysis buffer (w Triton-X-100) 
 
Antibodies: 
 Anti-HSP27 antibody 
 Anti-PECAM antibody 
 HRP-conjugated anti-rabbit 
 HRP-conjugated anti-goat 
 
PAEC seeded in 10 cm culture dishes were either kept as static non-treated control 
cells, treated with elastase or exposed to shear stress. After treatment, the cells were 
washed in ice cold PBS(-) and disrupted in 1 ml lysis buffer (w/o Triton-X-100). The 
lysates were ultra-centrifuged at 105 g at 4°C for 1 hour. The supernatants containing 
the cytosolic fraction were taken off and the pellets containing the particulate 
fraction were re-suspended in 300 µl lysis buffer (w Triton-X-100) and re-centrifuged at 
104 g for 10 min at 4°C. The supernatants were collected and defined as the 
membrane fraction (Triton-X-100 soluble fraction) whereas the remaining pellet 
contained the Triton-X-100 insoluble fraction. The relative amounts of HSP27 in the 
membrane fraction were determined densitometrically by Western blotting using an 
anti-HSP27 antibody (see table 2). The membranes were re-probed with an anti-
PECAM antibody to ensure equal loading. The mean amount of HSP27 (expressed as 
the ration between HSP27 and PECAM) in the membrane fraction in control cells was 
set to 100% and all other treatment conditions were compared to this group. 
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Self-made ELISA for measuring co-precipitation 
 
Reagents: 
 Washing buffer (bFGF ELISA kit) 
 Stop solution (2N sulfuric acid; bFGF ELISA kit) 
 TMB 
 
Buffers and solutions: 
 PBS(+) 
 D-blocking buffer 
 
Antibodies: 
 Anti-HSP27 antibody 
 Anti-phospho-HSP27 antibody 
 HRP-conjugate bFGF antibody (bFGF ELISA kit) 
 
For determining possible interaction between bFGF and HSP27, a self-made ELISA 
was established (figure 11). In this procedure, the wells of a 96 well plate were 
coated for 2 hours at RT with either a anti-HSP27 antibody or a phospho-specific 
HSP27 antibody both with a concentration of 20 µg/ml in PBS(+). After coating with 
either of the two antibodies, non-bound antibodies were washed off the wells with 
washing buffer and finally blocked with D-blocking buffer for 5 min at RT. Lysates from 
PAEC were added to the wells either natively or after denaturing (boiling for 5 min). 
The boiling was done to destroy the protein-protein interactions, which thereby 
Figure 11: Co-precipitation of HSP27 and 
bFGF. The wells of a 96-well plate were 
coated with an anti-HSP27- or a phospho-
specific HSP27 antibody. Lysates were 
added and the HSP27 or the phospho-
HSP27 (   ) was captured by the antibody. 
If bFGF (   ) and HSP27 or phospho-HSP27 
are interacting, bFGF will be pulled down 
together with the HSP27. The amounts of 
bFGF in the wells were detected by an 
anti-bFGF antibody directly HRP-coupled.  
E E
 
Materials and methods 
 53 
functioned as a negative control for HSP27 and bFGF interaction. Unbound proteins 
were washed off 3 times with washing buffer followed by incubation with an 
antibody against bFGF (50µl) directly HRP-conjugated to for 2 hours at RT. After three 
washings, a substrate for horseradish peroxidase, TMB was added to each well. After 
30 min the reaction was stopped with 2N sulfuric acid forming a yellow reaction 
product, which was quantified by recording the optical density (OD) at 450 nm.  
 
Phosphorylation assays for HSP27 
 
Determination of HSP27 phosphorylation was associated with some difficulties. The 
most straightforward approach would have been the determination of the 
phosphorylation by Western blotting using a phospho-specific antibody. However, 
the phospho-specific antibodies used in this study were not suitable for Western 
blotting. Therefore, other methods had to be used for examining the HSP27 
phosphorylation.  
 
Phosphorylation determined by a self-made ELISA 
 
Reagents: 
 Washing buffer (bFGF ELISA kit) 
 Stop solution (2N sulfuric acid; bFGF ELISA kit) 
 TMB 
 
Buffers and solutions: 
 PBS(+) 
 D-blocking buffer  
Antibodies: 
 Anti-HSP27 antibody 
 Anti-phospho-HSP27 antibody 
 HRP-conjugated anti-mouse antibody 
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The cell lysates used for this assay were from PAEC either kept as non-treated controls 
or treated with elastase or heat shock (42°C) for 2 hours each. In this self-made ELISA 
(figure 12), the wells of a 96 well plate were coated with a rabbit anti-HSP27 antibody 
(20 µg/ml in PBS(+)) (coating antibody) for 2 hours at RT. 
 As described previously, unbound coating antibodies were washed off by washing 
buffer (3 x 5 min) from R&D systems and the parts of the wells not bound by coating 
antibody were blocked with D-blocking buffer for 5 min at RT. Cell lysates were 
added to the coated wells and incubated for 2 hours at RT followed by a washing 
step to wash off unbound proteins. As detecting antibody a phospho-specific HSP27 
antibody (20µg/ml in PBS(+)) was used, which was incubated for 2 hours at RT. An 
anti-mouse HRP-conjugated secondary detecting antibody was added to the wells 
and left for 1 hour at RT before washing 3x 5 min with washing buffer. The substrate 
for horseradish peroxidase, TMB, was added to the wells for 30 min at RT in dark and 
the reaction was terminated by 2N sulfuric acid creating a yellow the reaction 
solution which could be read at 450 nm in a spectrophotometer and thereby the 
changes in phosphorylation status of HSP27 was expressed as changes in OD.  
 
Phosphorylation determined by immuno-precipitation  
 
Reagents: 
 Protein-A magnetic coupled micro-beads 
 
 
 
Figure 12: Detection of HSP27 
phosphorylation. The wells of a 96-well 
plate were coated with a rabbit anti- 
HSP27 antibody. The total amount of 
HSP27 (blue triangles) in the lysate was 
thereby pulled down. A mouse phospho-
specific HSP27 antibody (grey form) was 
detecting the phosphorylated HSP27 
(light blue circles). A horseradish 
peroxidase conjugated secondary 
antibody (purple form) labeled the 
phopsho-specific HSP27 antibody. 
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Buffers and solutions: 
 12% SDS-PAGE 
 Lysis buffer (w Triton-X-100) 
 SDS sample/loading buffer 
 
Antibodies: 
 Anti-phospho-serine antibody 
 Anti-HSP27 antibody 
 HRP-conjugated anti-rabbit antibody 
 
Cell lysates were prepared, as described previously, from PAEC treated with or 
without elastase. Protein aliquots of 300 µg each were mixed with a phospho-specific 
serine antibody (0.25 µg/100 µg protein) and protein-A magnetic coupled micro-
beads (50µl) for 30 min on ice. The mixtures were loaded onto MACS columns which 
were placed onto a strong magnet (figure 13). The mixtures were slowly passing 
through the columns, and the protein-antibody-magnetic-bead complexs were 
retained in the columns. When all of the solution had passed through the columns 
they were washed 3 times with lysis buffer (1 ml). 20 µl of hot (95°C) SDS 
sample/loading buffer (see solutions in the Western blot section) was added to the 
column and incubated for 5 min. Subsequently, 50 µl hot sample/loading buffer was 
Figure 13: Immuno-precipitation by MACS columns. 
Cell lysates were incubated together with an anti-
phopsho-serine antibody and protein-A coupled 
magnetic beads for 30 min on ice. Subsequently, 
the mixtures were passed through the columns and 
after washing, hot SDS sample/loading buffer was 
added to the columns. The eluted proteins were 
separated on a 12% SDS-PAGE and immuno-blotted 
with an anti-HSP27 antibody. 
HSP27
Anti-phospho-
serine antibody
Magnet
Magnetic 
bead
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applied to the columns and the retained proteins was thereby eluted from the 
columns. Eluates were separated by 12% SDS-PAGE and immuno-detection was 
done with an anti-HSP27 antibody. The mean phosphorylation of HSP27 of control 
cells was set to 100% and all other treatment conditions were compared to this 
group.  
 
Phosphorylation determined by isoelectric focusing 
 
Buffers and solutions: 
 IEF-gel 
 IEF solubilization buffer 
 Overlay buffer 
 Cathode buffer 
 Anode buffer 
 IEF washing buffer 
 Transfer buffer 
 A-blocking buffer  
 
Antibodies: 
 Anti-HSP27 antibody 
 HRP-conjugated anti-mouse 
 
Isoelectric focusing (IEF) is electrophoresis in a pH gradient set up between cathode 
and anode. Proteins will be positively charged at pH values below their isoelectric 
point (IpH) and negatively charged above. This means that proteins will migrate 
towards their IpH. Phosphorylation of a protein increases its negative charge and 
thus increases the mobility of the protein towards the acidic (anode) region of the IEF 
gel.  
 The following protocol is based upon (Ploegh, 1995). Porcine aortic endothelial cells 
exposed to shear stress for 0, 30, 60 or 120 min. were after treatment lysed in lysis 
buffer containing the non-ionic detergent Triton-X-100, as described previously. To 
obtain reproducible separations of proteins by charge, the ionic strength of the 
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samples must be as low as possible and hence the salt concentration was reduced 
by dialyzing each sample in dialyzing tubes (10 kDa cut-off) by centrifugation for 
approximately 30 min at 4°C. The sample volume was thereby reduced by 85%. The 
protein samples were subsequently diluted 1:4 with IEF solubilization buffer and 
loaded onto a 13.5% IEF-gel containing urea and ampholytes. The gel was casted in 
the large electrophoresis chamber from Bio-Rad (16 cm x 18 cm x 0.1 cm), also used 
in Western blotting.  The stacking gel normally used in protein electrophoresis was 
omitted. After loading of the samples, an overlay buffer was put on top of the 
samples to avoid contact between proteins and the cathode buffer, which was filled 
in the upper chamber. The lower chamber was filled with the anode buffer. A 
voltage of 400 Volts was applied to the gel over night and the following day the 
voltage was increased to 600 Volts for 1 hour.  
 For blotting the proteins onto a nitrocellulose membrane it was necessary to 
remove the non-ionic detergent from the gel, since it reduces the amount of proteins 
transferred to the membrane. Furthermore, SDS has to be bound to the protein in the 
gel in order to transfer them from the gel to the membrane. Both tasks were 
accomplished by washing the gel in washing buffer (5 x 10 min). After washing, the 
proteins were transferred to a nitrocellulose membrane by semi-dry transfer 
technique, as described above. The membrane was blocked with A-blocking buffer 
followed by incubation with an anti-HSP27 antibody in A-blocking buffer. The bound 
primary antibodies were detected by a HRP-conjugated anti-mouse antibody and 
viewed as described for Western blot. The data are expressed as the procentage of 
the amount of phosphorylation out of the total amount of detected protein within 
each treatment. 
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Figure 14: PACE for measurement of 
HSP27 phosphorylation. The principles 
in this assay are the same as 
described previously (see the section 
”phosphorylation determined by a 
modified ELISA”).The new with this 
method is however, that the 
detection of the phospho-HSP27 is 
done within the cells instead of 
utilizing cell lysate. 
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Phosphorylation determined by Phosphospecific antibody Cell-
Based ELISA (PACE)  
 
Media: 
 DMEM (10%) 
 DMEM (1%) 
 
Reagents: 
 TMB 
 
Buffers and solutions: 
 PBS(-) 
 PBS/Triton 
 4% formaldehyde 
 H2O2 
 C-blocking buffer 
 E-blocking buffer 
 
Antibodies: 
 Anti-phospho-HSP27 
 HRP-conjugated anti-rabbit 
 
 
The following protocol is based upon Versteeg et. al 2000 (Versteeg et al., 2000) 
(figure 14). PAEC were seeded in a 96-well plate. When they were confluent, the 
medium was changed from DMEM (10%) to DMEM (1%). The cells were kept as non-
treated controls or treated with elastase for 2 hours at 37°C, as described previously. 
After treatment, the cells were fixed with 4% formaldehyde for 20 min at RT and 
washed (3 x 5 min) with PBS/Triton. H2O2 (0.6%) in PBS/Triton was added for 20 min to 
quench the endogenous peroxidase. The cells were washed two times in PBS/Triton, 
blocked with E-blocking buffer for 1 hour and subsequently incubated overnight at 
4°C with an anti-phospho-HSP27 antibody diluted in C-blocking buffer. The next day, 
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the cells were washed (3 x 5 min) with PBS/Triton and incubated with a HRP-
conjugated anti-rabbit antibody in C-blocking buffer for 1 hour at RT. The cells were 
washed (3 x 5 min) with PBS/Triton and twice with PBS(-). Subsequently, the cells were 
incubated with TMB in dark, creating a bluish solution which was measured in a 
spectrophotometer at a wave length of 720 nm after 30 min. The mean OD in control 
cells was set to 100% and all other treatment conditions were compared to this 
group. 
 
Fluorescence-Activated Cell Sorter (FACS) 
 
Reagents: 
 CellWASH 
 Propidium iodide 
 Silicone solution 
 
Buffers and solutions: 
 Elastase 
 Citrate buffer 
 10% formaldehyde 
 
Antibodies: 
 Anti-bFGF antibody 
 FITC-labled anti-rabbit antibody 
 
Inhibitiors: 
 Abxicimab 
 Elastatinal 
 GF109203X 
 
FACS was used for analyzing the amount of bFGF on the cell surface. Basic FGF is a 
cytosolic protein, however, it is in the literature suggested that bFGF is released 
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through the plasma membrane (Engling et al., 2002;Backhaus et al., 2004;Nickel, 
2003). If this would be correct, it should be hypothesized that an anti-bFGF antibody 
would be able to recognize the bFGF protein sticking out of the membrane after 
elastase treatment (figure 15). By labeling the first antibody with a fluorescence 
labled secondary antibody the number of cells exposing bFGF on their surface could 
be measured by flow cytometry. To investigate whether the elastase acts via the 
matrix or directly on the cell or its integrins, two different protocols were followed, 
one for cells attached to the matrix during treatment and one for cells kept in 
suspension during treatment.  
 
Protocol for adherent cells  
 
Passage 2-3 of PAEC was seeded in a 24 well plate until they were app. 90% 
confluent. The cells were treated with elastase (as described previously). 30 min prior 
to the end of the treatment, propidium iodide (PI, 1:100) was added to the cells. PI is 
a compound, which is binding to double-stranded DNA, meaning it has to cross the 
plasma membrane, which it only can do in non-viable cells. Hence, the PI staining 
was done in order to make sure that only non-permeabilized cells were used for the 
measurement of the bFGF cell surface staining. As positive control for permeabilized 
cells the PKC inhibitor, GF109203X, was used, since it in high concentrations causes 
cell damage. 
 After 2 hours of elastase exposure, the medium was taken off and the cells were 
washed with 200 µl citrate buffer followed by incubation in the same amount of 
citrate buffer at 37°C until the cells were detached from the plate (approximately 1 
hour). Citrate buffer was used as a non-enzymatic form of detachment of cells, 
which in this situation was preferable, since an enzymatic reaction might influence 
Figure 15: FACS analysis of bFGF cell surface 
localization. Anti-bFGF antibodies were 
detecting the bFGF only on the membrane 
of non-permeabilized cells (propidium 
iodide (PI) negative). The bFGF antibodies 
were labeled by a fluorescent conjugated 
secondary antibody, which could be 
measured by flow cytometry. 
 
bFGF
bFGF
bFGF
PI
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the bFGF distribution in the cells. After detachment, the cells in the citrate buffer 
were fixed in 100 µl 10% formaldehyde for 10 min at RT. For washing off the 
formaldehyde, 1 ml cellWASH was added to each tube and centrifuged for 5 min at 
3000 rpm at RT. The Eppendorf tubes were turned upside-down to pour out the liquid 
leaving the cells in the tubes in app. 100 µl liquid. An anti-bFGF antibody in PBS was 
added to the cells and incubated for 30 min at RT. To wash off unbound antibodies, 
1 ml CellWASH was added to the each sample, centrifuged for 5 min. at 3000 rpm 
and again the Eppendorf tubes were turned to pure out the liquid leaving the cells in 
app. 100 µl liquid. As secondary antibody, a FITC-labled anti-rabbit antibody in PBS(-) 
was used to detect the anti-bFGF antibodies, which were adhering to the bFGF on 
the cell surface (figure 14). The cells were incubated with the secondary antibody for 
30 min in dark at RT and subsequently, the cells were washed in 1 ml CellWASH, 
centrifuged and the liquid discharged. Finally, 300 µl CellWASH was added to each 
sample before measuring in the flow cytometer. The argon laser in the flow 
cytometer excited the FITC with a wave length of 488 nm and the emission wave 
length of 510 nm was measured. In some experiments, the elastase treatment was 
done in combination with the inhibitors Abciximab or Elastatinal added to the cells 1 
hour prior to elastase treatment. 
 The mean fluorescence in control cells was set to 100% and all other treatment 
conditions were compared to this group. 
 
Protocol for suspended cells 
 
Cells were seeded as described for adherent cells. Before elastase treatment, the 
cells were detached from their matrix with 200 µl citrate buffer (app. 1 hour at 37°C). 
Eppendorf tubes were coated with silicone, by submersing the tubes in silicone 
solution containing isopropanol for 10 min at RT, followed by washing 3 times in 
distilled water. The coating was done in order to prevent cells from adhering to the 
Eppendorf tube during the elastase treatment and thereby ensuring that the cells 
were kept in suspension. The cells were centrifuged down (5 min at 3000 rpm at RT) 
and the citrate buffer was carefully discharged. DMEM medium (200 µl) containing 
1% FCS was added to each Eppendorf tube containing the cells. Elastase (0.5 U/ml) 
was added to each tube and left for incubation at 37°C for 2 hours.  
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 The following steps were the same as described for adherent cells after elastase 
treatment. 
 
Fast Activated Cell-Based ELISA (FACE) 
 
Media: 
 DMEM (10%) 
 DMEM (1%) 
 
Reagents: 
 TMB 
 
Buffers and solutions: 
 PBS(-) 
 4% formaldehyde 
 C-blocking buffer 
 F-blocking buffer 
 
Antibodies: 
 Anti-bFGF 
 HRP-conjugated anti-rabbit 
 
With some modifications of the PACE method, it was possible to determine the 
amount of bFGF on the cell surface. This assay was called Fast Activated Cell-Based 
ELISA (FACE; adapted form the company Active Motif; Rixensart, Belgium) instead of 
PACE, since this assay has nothing to do with phosphorylation. The protocol is 
basically the same as described for PACE, however, the cells should not be 
permeabilized and hence, no Triton-X-100 was used. Briefly, PAEC were seeded in a 
96-well plate, stimulated with elastase for 2 hours or kept as controls and fixed with 
4% formaldehyde. The cells were washed 3 times in PBS(-), blocked with F-blocking 
buffer and subsequently incubated with an anti-bFGF antibody in C-blocking buffer 
overnight at 4°C. The next day, the cells were washed with PBS(-) and incubated with 
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a HRP-conjugated anti-rabbit antibody in C-blocking buffer for 1 hour at RT. After 
three times wash, the cells were incubated with TMB in dark and the reaction was 
measured after 15 min at a wave length of 720 nm. The mean OD in control cells was 
set to 100% and other treatments were compared to this group. 
 
Immuno-histochemistry 
 
Media: 
 DMEM (10%) 
 DMEM (1%) 
 Leibovitz L-15 medium (1%) 
 
Buffers and solutions: 
 Elastase 
 Laminin type I 
 3.7% formaldehyde 
 D-blocking buffer 
 
Antibodies: 
 Anti-HSP27 antibody 
 Anti-bFGF antibody 
 FITC-labeled anti-rabbit antibody 
 
PAEC, passage 2-3, was used for immuno-staining, which was done on either non-
treated (control), shear stress- or elastase exposed cells. In case of shear stress 
experiments, the cells were seeded onto glass plates with a diameter of 4.5 cm pre-
coated with laminin type I. The shear stress experiments were performed in the 
parallel-plate system, as described previously. The control cells were kept static for as 
long as the shear stress treatment. In the case of elastase exposure, the cells were 
seeded on 1 cm cover slips pre-coated with laminin type I in a 24 well plate. The 
elastase treatment (0.5 U/ml, 2 hours) was performed as described previously. 
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 After treatment with either shear stress or elastase, the medium was discarded and 
the cells were fixed in 3.7% formaldehyde overnight at 4°C. The next day, the 
formaldehyde was washed off and D-blocking buffer was used to prevent unspecific 
binding of antibody to the cover slips. After 20 min of blocking, the first antibody 
(either an anti-bFGF- or an anti-HSP27 antibody) was applied to the cells diluted in D-
blocking buffer for 1 hour at RT. Unbound and unspecific bound first antibody was 
washed of in PBS(-) before a FITC-labeled anti-rabbit diluted in D-blocking buffer was 
applied to the cells and incubated in dark for 30 min at RT. Finally, the cells were 
washed and the cover slips with the cells were inverted and glued to an object glass. 
Subsequently, the cells were visualized in a Zeiss LMS 410 invert laser scan microscope 
(Ziess, Munich, Germany) with an excitation wavelength of 543 nm and an emission 
wavelength of 578 nm. As controls, cells stained with only the secondary antibody 
were used. 
 
Statistic 
 
All the statistical analysis was performed with Sigma Stat version 2.0. Data are 
expressed as mean ± SEM. Differences between values were considered statistically 
significant if p≤0.05. In cases where only two values are compared, a paired t-test 
was utilized for statistical testing. When more than two experiments were compared, 
a one-way ANOVA on Ranks was performed to test for differences compared to 
control cells. To identify the differences a Dunn’s method was used. 
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The role of proteases in bFGF release 
 
Shear stress, elastase activity and bFGF release 
 
A 3 fold higher elastase activity was observed in the conditioned medium from shear 
stress exposed porcine aortic endothelial cells (laminar shear stress (16 dyn/cm2)) 
compared to static control (p<0.05; n=6; figure 16). Likewise, the bFGF concentration 
in the conditioned medium from shear stress exposed cells was about 5-fold higher 
than in the supernatant of static control cells (p<0.05; n=9). This increase was 
abolished upon unspecific inhibition of serine proteases by aprotinin (p<0.05; n=9; 
figure 17).  
 
Elastase treatment and bFGF release 
 
It has previously been shown that elastase is a protease able to induce a release of 
bFGF when applied to endothelial cells (Buczek-Thomas & Nugent, 1999). Therefore, 
in the present study experiments were performed with application of porcine 
pancreatic elastase to PAEC. As control, it was shown that conventional elastase as 
obtained from SERVA (see methods) was able to cleave the same elastase specific 
substrate (MeOSuc-Ala-Ala-Pro-Val-pNa) as the endogenous elastase detected in 
Figure 16. Effect of shear stress on 
elastase activity. Exposure to shear 
stress significantly increased the 
elastase activity in the supernatant 
of PAEC. A specific substrate for 
elastase (MeOSuc-Ala-Ala-Pro-Val-
pNA) was applied to the 
conditioned medium of either static 
control - or shear stress exposed 
porcine aortic endothelial cells. By 
cleavage of the substrate the 
solution turned yellow allowing to 
measuring the reaction product at 
450 nm. A standard curve was 
performed to convert the 
measured optical densities (OD) 
into a concentration (mU/ml). The 
bar graphs represent means ± SEM. 
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the supernatant of shear stress exposed cells. The cleavage occurered in a 
concentration dependent manner and was inhibited by the specific elastase 
inhibitor, Elastatinal (figure 18). Therefore, this conventional elastase was used to 
assess the possibility that the increased elastase activity after shear stress has a 
functional role regarding bFGF release.  Static endothelial cells were incubated with 
different concentrations of elastase (0; 0.1; 0.3; 0.5; 1.0 and 2.0 U/ml), resulting in a 
Figure 18. Activity of conventional 
elastase. Conventional porcine 
pancreatic elastase cleaved the 
same substrate (MeOSuc-Ala-Ala-
Pro-Val-pNA) as utilized in the 
endogenous elastase activity 
assay in a concentration 
dependent manner (n=4). In 
some experiments (n=2) a 
specific inhibitor of elastase, 
elastatinal, was added to the 
reaction solution. Black circles 
represent elastase treatment; 
white circles represent elastase 
treatment in combination with 
elastatinal. 
 Elastase concentration (U/ml)
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Figure 17. Effect of shear stress on bFGF release. The shear stress induced bFGF 
release was abolished by protease inhibition. Porcine aortic endothelial cells were 
either left static (control) or exposed to shear stress (16 dyn/cm2) for 2 hours. Basic 
FGF concentration was measured in the conditioned medium. The last bar 
represents the bFGF release after shear stress exposure in combination with an 
unspecific serine protease inhibitor, aprotinin. The bar graphs represent means ± 
SEM. *p<0.05 compared to control. #p<0.05 compared to shear stress. n=9.  
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concentration depended release of bFGF from the cells (p<0.05, 2 U/ml compared 
to 0 U/ml; n=9; figure19A). Note that an elastase concentration of 0.5 U/ml resulted in 
a 2 fold higher bFGF release compared to non-treated control cells (p<0.05; n=8; 
figure 20A). At this elastase concentration, the cells looked healthy and did not stain 
positive for propidium iodide (PI) (no significant difference between untreated 
(control) and treated cells (elastase); p<0.01 compared to permeabilized cells 
(perm); n=3-5; figure 20B). Since it is favorable to use as low a concentration of the 
enzyme as possible, 0.5 U/ml elastase was utilized in all the following experiments 
unless stated otherwise. 
 The above results indicate that elastase induces bFGF release in a way other than 
membrane damage. To investigate the mechanism which could be involved in the 
release, cells were treated with elastase in combination with an inhibitory antibody 
against integrin αvβ3 (Abxicimab), based on a previous study, showing that shear 
stress induced bFGF release could be abolished by inhibition of the integrin αvβ3 
(Gloe et al., 2002). This integrin inhibition showed a reduction in the elastase 
mediated bFGF release (p<0.05, elastase (Ela) + Abxicimab (Abx) compared to 
elastase; n=7; figure 21). In contrast, an inhibitory antibody against integrin α6 (CD49) 
or an unspecific IgG did not cause any reduction in the bFGF release (NS; n=4). 
Figure 19. Basic FGF release after elastase treatment. Exogenously added 
elastase increased the bFGF release from static cells in a concentration 
dependent manner. Porcine pancreatic elastase was added to the medium of 
static endothelial cells at increasing concentrations (0; 0.1; 0.3; 0.5; 1 and 2 U/ml). 
After 2 hours, the bFGF concentration (pg/ml) in the conditioned medium was 
measured (ELISA). Bar graphs represent means ± SEM. *p<0.05 compared to non-
treated control cells (0 U/ml). n=9. 
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Figure 20. Elastase treatment with a concentration of 0.5 U/ml. A. Exogenously added elastase 
significantly increased the bFGF release from static cells. Cells were either left untreated (control) 
or treated with porcine pancreatic elastase (0.5 U/ml). The concentration of bFGF (pg/ml) in the 
conditioned medium was measured after 2 hours of treatment. Bar graphs represent the bFGF 
release expressed as % of the level before elastase treatment (control). *p<0.05 compared to 
control. n=8. B. Exogenously added elastase caused no cell damage, since treated cells were not 
PI positive. Cells were either kept as non-treated control cells, treated with porcine pancreatic 
elastase (0.5 U/ml, 2 hours) or with GF109203X (permeabilized (perm)), a PKC inhibitor, which in 
high concentrations cause cell damage (functions as a positive control for PI staining). The bar 
graphs represent the fraction of cells which were stained positive for PI pr. 3000 counted cells. 
**p<0.01 compared to permeabilized cells (perm). NS: not significant difference between control 
and elastase treated cells. n=3-5. 
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Figure 21. Selective inhibition of 
elastase mediated bFGF release 
by an αvβ3 antibody. Porcine 
aortic endothelial cells were 
either treated with porcine 
pancreatic elastase (0.5 U/ml, 2 
hours) alone or in combination 
with the inhibitory antibodies 
against integrin αvβ3 (Abxicimab 
(Abx) 0.5 µg/ml), integrin α6 
(CD49, 1.0 µg/ml) or an 
unspecific IgG (1.0 µg/ml). The 
bFGF concentration (pg/ml) was 
subsequently measured in the 
conditioned media. Ela denotes 
elastase. The bar graphs 
represent the bFGF release 
expressed as % of elastase 
treatment. *p<0.05 compared to 
elastase. n=4-7. 
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The bFGF translocation in endothelial cells 
 
bFGF translocation towards the cell membrane 
 
To evaluate the possibility that bFGF is released through the membrane, immuno-
staining of bFGF in control, shear stress exposed or elastase treated cells was 
performed. Non-treated control cells displayed primarily a diffuse perinuclear 
distribution of bFGF, whereas shear stress exposed as wells as elastase treated cells in 
addition clearly displayed a marked staining of the cell membrane. Figure 22 show 
representative pictures as they appeared in 3 independent experiments. 
 
Elastase-mediated bFGF translocation 
 
By utilizing the FACE method, the cell surface localization of bFGF after elastase 
treatment was confirmed. Treatment of cells with increasing concentration of 
elastase (n=5) showed a concentration-dependent increase in the amount of bFGF 
Figure 22. Immuno-histochemisty of bFGF.  Subcellular localization of bFGF in PAEC 
visualized by immuno-histochemistry showing translocation of bFGF towards the plasma 
membrane upon shear stress and elastase treatment. Direct immuno-fluorescence was 
performed on cells kept as non-treated control cells or cells exposed to shear stress (16 
dyn/cm2, 2 hours) or treated with elastase (0.5 U/ml, 2 hours). After treatment, cells were 
fixed, permeabilized and stained with a polyclonal rabbit anti-bFGF antibody followed by 
incubation with a fluorescent-labeled anti-rabbit antibody. Representative pictures from 3 
independent experiments. 
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at the cell surface, with a significantly higher cell surface staining at an elastase 
concentration of 1.5 U/ml (p<0.05, 1.5 U/ml compared to 0 U/ml; figure 23). 
 
Matrix-dependent bFGF translocation  
 
In addition to FACE, FACS analysis further verified, that there was significantly more  
bFGF at the cell surface after elastase treatment compared to non-treated control 
cells (1.5 fold; p<0.05; n=13; figure 24A). The amount of cell surface bFGF was 
reduced by a specific elastase inhibitor, elastatinal, which was added to the 
medium during elastase treatment (p<0.05 elastase (Ela) + elastatinal compared to 
elastase treatment; n=9; figure 24A). Furthermore, the elastase mediated 
translocation was significantly reduced by inhibition of integrin αvβ3 (p<0.05 elastase 
(Ela) + Abxicimab (Abx) compared to elastase treatment; n=13; figure 24A). In 
contrast, no translocation of bFGF was observed when the endothelial cells were 
detached from the matrix and kept in suspension during elastase treatment (NS; n=7; 
figure 24B).  
0 0.5 1.0 1.5
C
e
ll 
su
rf
a
c
e
 b
F
G
F
%
 o
f 
0
 U
/m
l
0
60
80
100
120
140
160
Elastaseconcentration (U/ml)
*
Figure 23. Quantitative analysis of 
bFGF cell surface localization by Fast 
Activated Cell-based ELISA (FACE). 
Exogenously added elastase 
increased the amount of bFGF at the 
cell surface in a concentration 
dependent manner. Porcine aortic 
endothelial cells were seeded in a 96-
well plate and subjected to different 
concentrations of porcine pancreatic 
elastase (0, 0.5, 1 and 1.5 U/ml). After 
2 hours of treatment, the cells were 
fixed and kept non-permeabilized, 
whereby the bFGF on the cell 
membrane could be detected by a 
specific anti-bFGF antibody. The bar 
graphs represent the bFGF on the cell 
surface expressed as % of non-
treated control. *p<0.05 compared to 
non-treated cells (0 U/ml). n=5.  
 
Results 
 
 72 
 
Involvement of HSP27 in bFGF release 
 
HSP27 phosphorylation 
 
The phosphorylation of HSP27 during shear stress exposure of endothelial cells has 
previously been shown (Azuma et al., 2001;Li et al., 1996) and was here verified by 
isoelectric focusing (IEF). Figure 24A shows four different bands separated on a pH-
gradient gel. The upper band represents the non-phosphorylated isoform (NP), 
whereas the three lower bands represent the mono-, the di- and the tri-
phosphorylated isoforms denoted P1, P2, and P3, respectively. The individual bands 
were quantified by densitometry and the percentage of total phosphorylation was 
calculated and graphically illustrated in figure 24B (n=2). Elastase treatment was also 
Figure 24. Flow cytometry analysis of bFGF cell surface localization. A. Inhibition of elastase or 
integrin αvβ3 reduced the elastase induced cell surface localization of bFGF. The bFGF cell surface 
expression was detected by the corresponding FITC-labeled antibody in untreated (control), 
elastase treated (0.5 U/ml, 2 hours), elastase + elastatinal (specific inhibitor of elastase, 2µM) or 
elastase + Abxicimab (Abx) (inhibitor of integrin αvβ3, 0.5 U/ml) treated cells. The inhibitors were 
added to the cells 1 hour prior to the elastase treatment. After treatment the cells were detached 
from the culture plates without using a protease-based protocol and kept non-permeabilized. Ela 
denotes elastase. The bar graphs represent bFGF cell surface staining expressed as % of non-
treated control level. *p<0.05 compared to control, n=13; #p<0.05 compared to elastase. n= 9-13. B. 
Treatment with exogenous elastase did not cause bFGF translocation to the plasma membrane in 
cells kept in suspension. PAEC was detached with citrate buffer before elastase treatment and kept 
in suspension during treatment. The bFGF on the cell surface was measured in the suspended cells. 
The bar graphs represent bFGF cell surface staining expressed as % of non-treated control level. NS 
denotes not significant. n=7. 
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able to induce phosphorylation of HSP27 (figure 26 and 27). As shown in figure 25 the 
phosphorylation of HSP27 was significantly higher in endothelial cells treated with 0.5 
U/ml compared to untreated control cells (p<0.05; n=5) when measured by PACE. 
Moreover, the phosphorylation did not increase further with a higher concentration 
of elastase (1.5 U/ml NS from 0 U/ml; n=5). The administration of 0.5 U/ml of elastase 
induced a 1.4 fold higher phosphorylation in treated cells compared to non-treated 
control cells (p<0.05; n=4), which was in the same range as the phosphorylation  
Figure 25. Isoelectric focusing for determining HSP27 phosphorylation after shear stress exposure. 
Shear stress exposure of endothelial cells seemed to increase the phosphorylation of HSP27 in a 
time dependent manner. PAEC was either kept as static control cells or exposed to shear stress (16 
dyn/cm2 for 30, 60 or 120 min). After treatment, the proteins were separated on a pH-gradient gel 
according to their isoelectric point (IpH). After separation, the proteins were blottet onto a 
nictrocellulose membrane and detected with a monoclonal mouse anti-HSP27 antibody. A. Shows 
a blot with the four different phosphorylation isoforms on a representative blot (NP: Non-
phosphorylated, P1-3: Phosphorylated). B. Shows the densitometric data expressed as the 
percentage of HSP27 phosphorylation of the total HSP27 after each time point from two 
independent experiments.  
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caused by heat shock (42°C for 2 hours; n=4) measured by a self-made ELISA (figure 
27A). Furthermore, the elastase induced HSP27 phosphorylation seemed to be 
reduced after integrin αvβ3 inhibition (Abxicimab (Abx)) (n=5; figure 27B). 
Figure 26. PACE analysis of HSP27 
phosphorylation as a function of elastase 
concentration. Quantitative analysis of 
HSP27 phosphorylation by 
phosphospecific antibody cell-based 
ELISA (PACE), show HSP27 
phosphorylation after elastase treatment. 
Porcine aortic endothelial cells seeded in 
a 96-well plate were either kept as 
untreated (0 U/ml elastase) or treated 
with different concentrations of porcine 
pancreatic elastase (0, 0.5 or 1.0 U/ml) for 
2 hours. After treatment, the cells were 
permeabilized and the phosphorylation 
of HSP27 was detected by a 
phosphospecific HSP27 antibody. The bar 
graphs represent HSP27 phosphorylation 
expressed as % of the level in non-treated 
cells. *p<0.05 compared to untreated 
cells (0 U/ml). n=5. 
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Figure 27. HSP27 phosphorylation after elastase treatment with 0.5 U/ml. A. Lysates from PAEC from 
either control cells, elastase-treated cells (0.5 U/ml, 2 hours) or heat shock-treated cells (42°C, 2 
hours) were analyzed for heat shock protein 27 (HSP27) phosphorylation using a modified ELISA as 
described in the methods. The bar graphs represent HSP27 phosphorylation expressed as % of the 
level in non-treated cells. *p<0.05 compared to control. n=4. B. Lysates from either untreated 
(control), elastase treated cells (0.5 U/ml, 2 hours), E + Abxicimab (Abx) (integrin αvβ3 inhibition) or E 
+ SB202190 (p38 MAPK inhibition) were subjected to immuno-precipitation of phospho-serine. The 
precipitations were loaded in equal amounts on a 12% SDS-PAGE and probed with a polyclonal 
anti-HSP27 antibody as primary antibody. The upper panel shows a representative Western blot, 
whereas the lower panel shows the densitometric data expressed as % of the non-treated control 
level. Ela denotes elastase. n=5. 
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p38 MAP kinase activation 
 
As mentioned in the introduction, HSP27 can be phosphorylated either via the p38 
MAP kinase pathway or the p42/44 MAP kinase pathway. In the present study, 
specific inhibition of p38 MAP kinase caused a reduction in the HSP27 
phosphorylation (n=5; figure 24B). To further assess for the role of p38 MAP kinase, 
Western blots were performed to investigate the phosphorylation of p38 - as well as 
p42/44 MAP kinase during elastase treatment. As seen in figure 27A, elastase 
treatment lead to a 1.8 fold higher p38 MAP kinase phosphorylation compared to 
non-treated control cells (p<0.05; n=4). In contrast, the p42/44 was not affected by 
the treatment (n=3; figure 28B). Furthermore, the phosphorylation of p38 MAP kinase 
was reduced by inhibition of integrin αvβ3 (n=4; figure 28A).  
 
Figure 28. Western blots for activation of p38 and p42/44 MAP kinase. A. The p38 MAP kinase was 
phosphorylated in an integrin αvβ3 dependent manner after elastase treatment. Upper panel 
shows a representative Western blot. Lysates from cells from either untreated (control), elastase-
treated (0.5 U/ml, 2 hours) or elastase + reopro (inhibitor of integrin αvβ3, 0.5 µg/ml) was separated 
on a 10 % SDS-PAGE, and immuno-blottet with a phospho-specific p38 MAP kinase antibody 
(lower bands). To ensure equal loading of protein, the membrane was re-probed with an anti-p38 
antibody (upper bands). Lower panel shows the densitometric data (ration of phospho-p38 to 
p38) expressed as % of the non-treated control level. * p=0.05 compared to control. n=4. Ela 
denotes elastase. B. The p42/44 MAP kinase was not phosphorylated after elastase treatment. The 
activation of the p42/44 is presented in a similar way as p38 activation (A). n=3. 
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HSP27 translocation 
 
To assess the possibility that HSP27 is a carrier for bFGF to the cell membrane, 
immuno-staining of HSP27 in control cells, shear stress exposed or elastase treated 
cells was performed. Figure 28 shows representative immuno-histochemistry pictures 
of subcellular localization of HSP27 as it appear in 3 independent experiments. HSP27 
displays a similar distribution pattern as bFGF (see figure 22), namely, after shear stress 
exposure as well as elastase treatment, HSP27, seemed to be localized in 
considerable amounts at the cell membrane.  
 In addition to immuno-histochemistry, measurements of the amount of HSP27 in 
membrane fractions of shear stress exposed- and elastase-treated cells together with 
their respective controls showed that significantly more HSP27 was found in the 
membrane fractions after the two treatments compared to their non-treated control 
cells  (6-fold increase after shear stress, p<0.05 compared to control n= 3; and 2.5 
fold increase after elastase treatment, p<0.05 compared to control, n=6; figure 30A 
and b, respectively). Moreover, inhibition of integrin αvβ3 (Abxicimab (Abx)) or p38 
Control Shear stress Elastase treatment
Figure 29. Immuno-histochemistry of HSP27. Subcellular localization of HSP27 in porcine aortic 
endothelial cells visualized by immuno-histochemistry show a translocation of HSP27 towards the 
plasma membrane upon shear stress exposure or elastase treatment. Direct immuno-fluorescence 
was performed on cells kept as non-treated control cells or cells exposed to shear stress (16 dyn/cm2, 
2 hours) or treated with porcine pancreatic elastase (0.5 U/ml, 2 hours). After treatment, cells were 
fixed, permeabilized and stained with a polyclonal rabbit anti-hsp27 antibody followed by incubation 
with a fluorescent-labeled anti-rabbit antibody. Representative pictures from 3 independent 
experiments. 
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MAP kinase (SB202190) during elastase treatment resulted in a reduction in the 
amount of HSP27 in the membrane fraction (n=6; figure 30B). 
 
HSP27 and bFGF co-precipitation 
 
Co-precipitation of HSP27 and bFGF was determined by a self-made ELISA (see 
method section). First, the total amount of HSP27 (non-phosphorylated- plus 
phosphorylated-HSP27) was pulled down by an anti-HSP27 antibody. Second, only 
the phosphorylated-HSP27 was pulled down by a phospho-specific-HSP27 antibody. 
The amount of bFGF pulled down in both cases was detected by an anti-bFGF 
antibody. Lysate from control cells were either kept as native lysate or boiled (100°C, 
5 min) to destroy the expected interaction between bFGF and HSP27 which thereby 
was used as a negative control for the interaction. An 8-fold higher amount of bFGF 
was pulled down together with the total amount of HSP27 in native lysate compared 
to boiled lysate (p<0.05; n=4; figure 31, dotted bars). Likewise, in the case where only 
the phosphorylated HSP27 was pulled down, an 8-fold higher amount of bFGF was 
Figure 30. HSP27 in membrane fractions. Quantitative analysis of HSP27 translocation show 
increased HSP27 localization at the plasma membrane after shear stress exposure and elastase 
treatment. PAEC were kept either as controls, exposed to shear stress (16 dyn/cm2, 2 hours) (A) 
or treated with porcine pancreatic elastase (0.5 U/ml, 2 hours) with or without an inhibitory 
antibody against integrin αvβ3 (Abxicimab (Abx), 0.5 µg/ml) or a specific inhibitor of p38 MAP 
kinase (SB202190, 1µM) (B). The membrane fractionation was done according to the description 
in the method section. The upper panel shows a representative Western blot. Ela denotes 
elastase. The bar graphs represent densitometric data (HSP27 / PECAM) expressed as % of the 
control level. *p<0.05 compared to control. n=3 (A). n=6 (B). 
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measured in the native lysate compared to boiled lysate (p<0.05; n=3; figure 31, 
squared bars). 
N a t iv e  ly s a t e B o ile d  ly s a te
O
D
0 , 0 0
0 , 0 5
0 , 1 0
0 , 1 5
0 , 2 0
0 , 2 5 * *
Figure 31. Co-precipitaion of phospho-HSP27 and bFGF. Lysates from non-treated PAEC were 
added to wells of a 96-well dish pre-coated with either a rabbit anti-HSP27 antibody (dotted 
bars) or a mouse anti-phospho-HSP27 antibody (squared bars). The total amount of HSP27 and 
the phosphorylated HSP27 proteins in the lysate were thereby pulled down, respectively. By 
using either a mouse anti-bFGF or a rabbit anti-bFGF antibody, the amount of bFGF pulled 
down together with the total HSP27 or the phospho-HSP27 was detected, respectively. The 
lysates were either boiled (100°C for 5 min) prior its application to the wells to destroy the 
protein-protein interactions or kept native, by which the interactions are preserved. *p<0.05 
compared to pre-boiled lysate. n=3-4. 
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This study in cultured endothelial cells clearly showed that elastase, by interaction 
with the cellular matrix elicits a signaling cascade which initial step involves 
activation of integrin αvβ3. Through p38 MAP kinase signaling a phosphorylation of 
HSP27 is induced which is a prerequisite for the membrane translocation and finally 
release of bFGF from the intact cell.  Further proof of concept the study suggests that 
shear stress of a magnitude that exists in small arteries and arterioles may well serve 
as a physiologic stimulus for the elastase induced bFGF release. 
 In the following, the results found in present study will be discussed in three parts. 
The first part deals with the role of elastase in bFGF release. The second part 
concerns the intracellular pathway leading to the release of bFGF and in the last 
part, the role of elastase in mechanotransduction of shear stress will be discussed. 
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 bFGF release from endothelial cells 
 
Elastase is a protease which has been shown to liberate bFGF from the extracellular 
matrix of endothelial cells. However, the data presented in this study provide 
evidence for the ability of elastase to induce an active release of endogenous bFGF. 
Moreover, the findings point to the fact that bFGF is released from the cells directly 
through the cell membrane. 
 
Elastase as stimulus for bFGF release 
 
To assess the possibility that elastase is involved in the bFGF release, conventional 
elastase was exogenously applied to static endothelial cells. The treatment with 
elastase led to a concentration dependent release of bFGF. A similar concentration 
dependent elastase-mediated release of bFGF was also demonstrated by Buczek-
Thomas and Nugent (1999) in culture from lung pulmonary fibroblasts (Buczek-
Thomas & Nugent, 1999). In that study the authors postulated that the elastase 
induced bFGF release originates from the ECM (Buczek-Thomas & Nugent, 1999; Rich 
et al., 1996), where the bFGF is found bound to heparin sulfate proteoglycans (Yu et 
al., 1993; Nugent & Iozzo, 2000). Buczek-Thomas and Nugent (1999) argued that 
elastase might be able to release bFGF by digesting proteoglycan core proteins and 
showed that the bFGF release correlated with release of sulfated 
glycosaminoglycans (GAG). They thereby concluded that the mechanism of 
elastase-mediated bFGF liberation is likely through disruption of matrix proteoglycans 
(Buczek-Thomas & Nugent, 1999). The view that bFGF is released by proteolytic 
digestion from the ECM is supported by other studies (Rich et al., 1996; Saksela & 
Rifkin, 1990; Bashkin et al., 1989; Ishai-Michaeli et al., 1992; Whitelock et al., 1996).  
 In contrast to these findings, I argue that the elastase treatment can lead to a 
direct release of endogenous bFGF. The argument for this comes from the finding 
that the release could be abolished by the inhibition of the integrin αvβ3. If the bFGF 
was solely released from the matrix, this release should not be affected by a cell-
adhesion molecule. That bFGF indeed can be released from inside the cell and not 
only the matrix, has previously been demonstrated by Gloe et al. (2002) who 
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measured a decrease in the amount of bFGF within the cytoplasm after shear stress 
exposure of human umbilical vein endothelial cells (HUVEC). 
 One could argue that elastase in the concentration used here was lethal for the 
cells, since it is a degrading protein and could cause damage to the cells, which 
naturally would lead to an unspecific bFGF release. Cell damage as a mechanism of 
bFGF release was suggested by several groups (Hartnett et al., 1999; Rhoads et al., 
2000; McNeil et al., 1989; Brooks et al., 1991). In contrast, it was in the present study 
demonstrated that cells treated with elastase up to a concentration of 0.5 U/ml did 
not show any sign of membrane damage and did not stain positive for propidium 
iodide indicating that they displayed an intact cell membrane. Furthermore, since 
the release could be reduced by inhibition of the integrin αvβ3, cell damage cannot 
be the reason for the observed bFGF release during elastase treatment. Rather, the 
release must be a regulated and controlled process, which previously has been 
concluded from other studies (Mignatti et al., 1992; Florkiewicz et al., 1995; Florkiewicz 
et al., 1998; Gloe et al., 2002; Backhaus et al., 2004).  
 
The release of bFGF 
 
Even though the biological functions of bFGF are well characterized, only little is 
known about how bFGF is released from cells, since it lacks the signal sequence 
which is needed for classical protein secretion from the cell. In the present study, 
immuno-histochemistry pictures of bFGF could show that bFGF was localized at the 
cell membrane during elastase treatment in contrast to a more defuse subcellular 
distribution in control cells. This finding suggests that bFGF is released through the 
membrane. Further evidence for this statement comes from measurement of bFGF 
on the cell surface. 
 Basic FGF is a cytosolic protein normally not found on the cell surface. Measuring 
cell surface localization of a cytosolic protein is not commonly done and to my 
knowledge the present study is the first to determine cell surface localization of a 
cytosolic protein by FACE-technique. Furthermore, measuring bFGF on the cell 
surface by FACS was also a new idea and by setting up my own protocol I made it 
possible to quantify the cell surface localization of the protein. Thereby it was possible 
to show an elastase concentration-dependent cell surface localization of bFGF as 
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well as significantly more bFGF at the cell surface of elastase treated cells compared 
to non-treated control cells. That it is possible to measure bFGF on the cell outer 
surface means that the protein is being released from the cells directly through the 
cell membrane. The fact that bFGF can be detected by the antibody used in FACE 
and FACS is consistent with the view that the protein still is in the membrane but on its 
way out of the cell.  
 Alternatively to this view of how bFGF is being released, one study suggests a role 
of large granules in the bFGF secretion (Qu et al., 1998), while others report of no 
apparent bFGF localization in vesicular structures (Engling et al., 2002; Renko et al., 
1990). Other studies suggest bFGF to be released from cells via exocytosis (Piotrowicz 
et al., 1997; Mignatti et al., 1992) or membrane blebbing (Taverna et al., 2003). 
However, if bFGF was released by exocytosis it would not be possible to detect the 
bFGF on the cell surface. The Na+,K+-ATPase is the only protein suggested to play a 
role in the export by forming a complex with bFGF and thereby catalyzing the 
transport of the growth factor out of the cell (Florkiewicz et al., 1998). The ATPase 
could deliver a driving force for the transport of the relatively large bFGF molecule 
through the cell membrane. However, it remains to be studied further whether this 
mechanism played a role in our cell. 
 The conclusion that bFGF is released through the membrane is further supported by 
the studies showing that in CHO-cells GFP-labelled bFGF fused to dihydrofolate 
reductase (DHFR) is translocated across the cell membrane and thereby released in 
a folded conformation (Engling et al., 2002; Backhaus et al., 2004). This excludes 
another proposed transport patway, namely the ABC (ATP-binding cassette) 
transporter (Kuchler & Thorner, 1992), since ABC-transporter mediated protein export 
requires protein unfolding. 
 Heat shock proteins are proteins assisting protein folding and therefore, it might be 
speculated that they are able to assist bFGF through the membrane. In support of 
this idea, it has been shown that a heat shock protein, namely heat shock protein 27 
(HSP27), facilitates the release of bFGF from endothelial cells (Piotrowicz et. al 1997). 
This is supported by the fact that the HSP27 intervene in the control of cell growth 
and differentiation (Horman et al., 1999; Piotrowicz et al., 1995), two processes also 
known to be mediated by bFGF (Nugent & Iozzo, 2000). Moreover, it would be a 
mechanism allowing bFGF to be released in its folded form. In the following part, the 
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role of HSP27 in bFGF release is discussed along with a possible intracellular signaling 
pathway. 
 
The intracellular signaling cascade and bFGF release 
 
Searching for a signaling pathway leading to bFGF release the present study 
provides evidence for that both bFGF as well as HSP27 were translocated towards 
the cell membrane upon stimulation. Moreover, both proteins were detected in 
higher amount at the cell membrane upon elastase treatment. Interestingly, bFGF 
could be co-precipitated with the phosphorylated HSP27 indicating that these 
proteins closely interact with each other. 
 
Function of HSP27 in bFGF release 
 
HSP27 as visualized by immuno-staining was found to be translocated to the cell 
membrane in elastase-treated cells similar to bFGF. Quantitative analysis of the 
HSP27 translocation by membrane fractionation confirmed that more HSP27 was 
found at the plasma membrane after elastase treatment. The observation that both 
proteins are translocated towards the membrane upon stimulation strongly suggests 
that HSP27 functions as a carrier for bFGF to the cell membrane, similar as it has been 
shown for HSP90 and eNOS (Ortiz et al., 2004). 
 If this hypothesis is true, the two proteins must interact physically. Indeed, it could 
be shown that bFGF and HSP27 do interact, since bFGF could be pulled down 
together with HSP27. This was shown by a co-precipitating ELISA, which in the present 
study had to be established, since other co-precipitation assays were not 
appropriate in this case. It turned out that this ELISA was a more straight forward and 
more sensitive method than visualizing the co-precipitation by Western blotting. An 
interaction between HSP27 and bFGF has principally been shown before (Piotrowicz 
et al., 1997), but the present study now shows for the first time that it specifically is the 
phosphorylated form of HSP27 which is interacting with bFGF. This is concluded from 
the fact that the amount bFGF pulled down together with the phosphorylated HSP27 
was similar to the amount pulled down with the total (non-phospho- and phospho-
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HSP27) HSP27. As control, boiled lysate was used, and showed negative results, since 
the protein-protein interaction in that case is destroyed.  
 This finding strongly indicates that HSP27 has to be phosphorylated in order to bind 
to bFGF and therefore, phosphorylation seems to a prerequisite for bFGF release. In 
fact, it could be shown that HSP27 was phosphorylated during elastase treatment. 
The importance of phospho-HSP27 is in accordance with a study showing that 
phosphorylated HSP27 in migrating endothelial cells in a wound healing assay was 
localized at the membrane of the leading edge (Piotrowicz et al., 1998), which 
correlates with the localization of bFGF just in front of the migrating cells guiding the 
cells during migration (Nehls et al., 1998).  
 
HSP27 phosphorylation 
 
In present study, the shear stress-mediated phosphorylation was determined by 
isoelectric focusing (IEF), which is a well documented method for determination of 
protein phosphorylation; measuring HSP27 phosphorylation by this method has 
previously been verified by 32P-metabolic labeling (Li et al., 1996; Landry et al., 1992; 
Meier et al., 2001; Larsen et al., 1997). The reason for utilizing this technique and not 
Western blotting using a phospo-specific antibody was the lack of an appropriate 
phospho-HSP27 antibody. In IEF, the proteins are separated by charge, where 
phosphorylation of a protein is recognized as a shift in the mobility of the given 
protein. Therefore, no phospho-specific antibody had to be used. Most often the IEF 
is done in tube-gels; however, a self-established protocol for IEF in large slab gels was 
made, since the separation of the proteins was better and the handling of the gels 
easier. The disadvantage with the IEF is, however, that some contradictions exist in 
the literature regarding the isoelectric points (IpH) of the different phospho-isoforms 
of the HSP27. Therefore other approaches, such as self-made ELISA and PACE (see 
methods) were utilized in the present work to determine the HSP27 phosphorylation 
as a response to exogenous elastase treatment.  
 I was setting up my own ELISA and PACE, since at that time there was no 
commercial available ELISA- or PACE kit for phospho-HSP27. In these assays, a 
phospho-specific HSP27 antibody had to be used. As mentioned above, no 
phospho-HSP27 antibody was found to work in Western blotting; however, the 
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phospho-HSP27 antibody did work well in ELISA and PACE, which could be explained 
by the use of native proteins in these methods. By the self-made ELISA and PACE it 
was demonstrated that HSP27 phosphorylation was induced by shear stress as well as 
elastase treatment. The fact that other stimuli, such as shear stress (see below) and 
elastase as well as hypoxia and estrogen (Ishibashi et al., 2001; Ishibashi et al., 1995; 
Kuwabara et al., 1995; Albuquerque et al., 1998; Horman et al., 1999), resulting in 
bFGF release simultaneously also lead b  to HSP27 phosphorylation, supports the 
conclusion drawn from the present study, that HSP27 phosphorylation is prerequisite 
for bFGF release. 
 To be able to facilitate the release of bFGF from cells phospho-HSP27 and bFGF 
must be in the same place at the same time. Following HSP27 phosphorylation, some 
studies report that the protein is translocated to the nucleus in response to heat 
shock (Arrigo & Welch, 1987; Arrigo et al., 1988) or ATP-depletion (Loktionova et al., 
1996), whereas other studies do not show any redistribution of HSP27 to the nucleus 
upon heat shock. In spite of the contradictory reports, a HSP27 redistribution to the 
nucleus upon phosphorylation could be a way for HSP27 and bFGF to meet each 
other, as high amounts of bFGF are localized in nucleus (Arnaud et al., 1999; Quarto 
et al., 1991; Florkiewicz et al., 1991; Bugler et al., 1991; Claus et al., 2003). The latter 
was confirmed in the present study by immuno-staining. This finding fits very well to 
the studies stating that the high molecular weight (HMW) form of the bFGF is 
predominantly localized in the nucleus and the 18-kDa isoform not (Quarto et al., 
1991; Florkiewicz et al., 1991; Bugler et al., 1991), as well as that the HMW-bFGF is 
released in response to 17β-estradiol-stimulation (Piotrowicz et al., 1997) – also a 
known stimulus for HSP27 phosphorylation (Piotrowicz et al., 1995). However, the bFGF 
isoform released in this study has not been investigated. 
 HSP27 is either phosphorylated by the p38 MAPK pathway or the p42/44 MAPK 
pathway via MAPKAP kinase II (Rouse et al., 1994; Stokoe et al., 1992b) or by p38 
MAPK via PRAK (New et al., 1998). The data presented here provide substantial 
evidence for the involvement of p38 MAPK pathway, since the elastase-induced 
HSP27 phosphorylation was reduced by specific inhibition of p38 MAPK. The pathway 
was further dissected by demonstrating that elastase treatment led to p38 MAPK 
activation and not to p42/44 MAPK activation. This is in line with the finding that 
activation of integrin αvβ3 – being identified as a central player in the signaling 
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pathways studied here (will be discussed later) – does not affect the ERK1/2 (p42/44 
MAPK) pathway (Weyts et al., 2002). The explanation for the observed p38 MAPK and 
not p42/44 MAPK actiation could be that p38 MAPK activation is dependent upon 
specific integrin-matrix interactions, as demonstrated by Orr et al. (2005), whereas 
ERK1/2 activation does not seem to be dependent upon integrin-matrix interactions 
(Ponik & Pavalko, 2004; Weyts et al., 2002) but is rather activated in non-focal-
adhesion manner, such as receptor tyrosine kinases (Chen et al., 1999), G-protein-
coupled receptors (Gudi et al., 1996), or ion channels (Olesen et al., 1988).  
 
Elastase in mechanotransduction 
 
Shear stress-induced elastase activity 
 
A significant involvement of elastase contribute to the shear stress-induced bFGF can 
be deduced from several observations. Firstly there was indeed a significantly higher 
elastase activity was measured in the medium after shear stress compared to their 
static controls at the same time as endothelial cells released bFGF. Secondary, the 
fact that shear stress-induced bFGF release could be prevented by inhibition of 
serine proteases certainly implies a role of serine proteases in the bFGF release. These 
two findings confirm that elastase takes part in the translation of the mechanical 
signal (shear stress) into a biochemical signal within the cells ending up with bFGF 
release. That proteases must play an important role in mechanotransduction is 
supported by the finding that mechano-stimulation such as shear stress and stretch 
leads to an enhanced activation and release of cysteine proteases and MMP-2 
(Fukuda & Schmid-Schonbein, 2003; Rivilis et al., 2002). Among different serine 
proteases I focused in the present study on the role of elastase in shear stress-
induced bFGF release since yet unpublished results obtained from enzymograms, 
performed by other lab members, using different substrates like collagen, albumin 
and casein within the gel yielded no marked differences in proteolytic activity 
except for one digestive band at app. 20 kDa (the size of elastase). This band was 
much stronger after shear stress exposure compared to static cells, indicating that 
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elastase might be the main protease activated after shear stress (personal 
communication Gloe, T.).  
 
Shear stress- vs. exogenous elastase-mediated bFGF release 
 
The above discussed data suggest that the elastase is directly involved in the shear 
induced growth factor release. However, the exogenous elastase-mediated bFGF 
release was only 2-fold higher than control cells, which was less than the 10-fold 
increase in the release after shear stress, and additionally, the exogenous elastase 
concentration (0.5 U/ml) required to elicit a bFGF release was higher than the 
elastase concentration detected in the media after 2 hours of shear stress (0.015 
U/ml). The explanation for these contradictories could be that shear stress makes the 
cells more sensitive to the elastase by deformation of the cell during shear stress 
turning on some intracellular pathways (Dalle-Donne et al., 2001; Davies, 1995) which 
might enhance the cellular response to endogenous elastase. However, this does not 
seem to be the case, since shear stress and exogenously added elastase turn on a 
specific intracellular pathway involving integrin αvβ3, p38 MAPK activation and HSP27 
phosphorylation leading to the release of bFGF. 
 Furthermore, bFGF has been demonstrated to be directly or indirectly interacting 
with the α-subunit of the Na+,K+-ATPase and the ATPase has been suggested to be 
involved in the bFGF release (Florkiewicz et al., 1998). Hence, it might be possible that 
α-subunits of the Na+,K+-ATPase were translocated from intracellular storages to the 
plasma membrane upon shear stress to form more functional units of the ATPase in 
the membrane, as it has been observed in skeletal muscle cells as an acute response 
to exercise (Juel et al., 2001).  
 Other explanations for the relatively low level of elastase measured in the medium 
after shear stress and at the same time a high bFGF release compared to exogenous 
elastase treatment simply might be that during shear stress, the elastase is released 
not only to the medium but also directly into the matrix leaving only a small amount 
of elastase in the medium. Therefore, the elastase activity measured in the medium 
during shear stress may be underestimated. At the same time, the elastase which is 
released directly into the matrix during shear stress is already at its place of action. In 
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contrast, the exogenously added elastase has to diffuse into the cell layer and into 
the matrix in order to place its action. This means that a higher concentration of 
exogenous elastase is needed to gain a similar effect as endogenous elastase. 
Possibly only a small amount of the exogenously added elastase reaches the matrix, 
which also would explain the lower bFGF release during exogenously added 
elastase.  
 
Role of elastase in shear stress-induced bFGF release 
 
The results discussed above suggest that elastase is involved in the 
mechanotransduction of shear stress into bFGF release, but do not indicate a 
possible mechanism. In the past, proteases have been considered to act mainly 
degradative. However, in recent years studies have shown that proteases are able 
to remodel the ECM and thereby exposing cryptic fragments that can lead to 
initiation of intracellular signaling (matricryptin) (Preston et al., 2002; Geiger et al., 
2001; Mott & Werb, 2004; Faisal Khan et al., 2002; Koshikawa et al., 2000). Since the 
cells in the present study were primarily grown on laminin type I, and elastase is able  
to degrade this type of laminin into defined fragments (Kapur et al., 2005) it is 
tempting to speculate that the released and/or activated elastase observed during 
shear stress is an important initiator of the mechanotransduction by remodeling the 
matrix. This view adds a new perspective to some already well established models of 
mechanotranduction. It should be mentioned that it is not yet clear how shear stress 
eliciting a release or activation of elastase. This remains to be determined in further 
experiments.  
 For many years it has been widely accepted that the transfer of shear stress forces 
first occurs at the luminal cell surface recognized by local displacement of sensors on 
the cell surface (mechanoreceptors) (Davies, 1995). These mechanosensors can be 
cell surface proteins (Davies, 1995) or distinct mechanosensitive ion channels (Sachs, 
1988; Martinac et al., 1987) such as potassium channels (Olesen et al., 1988). It is 
believed that the stress activated mechanoreceptors transmit the mechanical signal 
into biochemical events by either one of two ways. One model suggests that the 
signal after being recognized at the luminal surface will be transferred into different 
part of the cell via second messengers (Davies, 1995). However, this model cannot 
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account for the transmission of shear stress into bFGF release, since this release was 
shown to be dependent upon the specific cell-adhesion molecule, integrin αvβ3 
(Gloe et al., 2002). A focal adhesion dependent mechnotransduction is in line with 
the second mechanotransduction model proposing that the recognized shear stress 
force at the luminal surface can be transmitted by deformation of the cytoskeleton 
to sites in the cell remote from the stimulus such as abluminal attachment sites which 
directly interact with integrins (Davies, 1995). There are, however, some 
contradictions between our results and the mentioned models of 
mechanotransduction: Davies (1995) and other authors (Chen et al., 1999; Burridge 
et al., 1988) suggest that the force is transmitted to the integrin from the luminal cell 
surface via the cytoskeleton, whereas the present study suggests that it is the shear 
stress-induced elastase activity and not the shear force directly that acts on the cell 
and thereby the integrin. The latter proposal is based upon the observations that, 
similar as for shear stress, also the exogenous elastase-mediated bFGF release in 
resting cells was prevented by inhibition of the integrin αvβ3.  
 
The role of integrin αvβ3 in mechanotransduction 
 
In both treatments, shear stress and elastase, the bFGF release was specifically 
dependent upon the integrin αvβ3, since inhibition of other integrins (mainly β1 
integrins) did not have any effect on the release (figure 20 and Gloe et al., 2002), 
suggesting that a specific signaling pathway was turned on by the two types of 
treatment. This is supported by Tzima et. al (2001) who by immuno-staining with the 
anti-αvβ3 antibody specific for the activated integrin (WOW-1) demonstrated that 
shear stress specifically activates integrin αvβ3 (Tzima et al., 2001). Moreover, the 
importance of this integrin in mechanotransduction in general is strengthened by the 
findings that pretreatment of endothelial cells by blocking anti-αvβ3 antibodies 
prevented the shear stress activation of ERK- and the JNK pathways as well as the IκB 
complex (Li et al., 1997; Bhullar et al., 1998).  
 That both shear stress- and exogenous elastase- induced bFGF release is critically 
dependent upon the same type of integrin does not only suggest that the release is 
mediated by a similar pathway but also that the release is critically dependent upon 
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cell-matrix interactions. The importance of the ECM in bFGF release mediated by 
elastase was demonstrated by measuring the cell surface localization of bFGF in 
elastase treated adherent and suspended cells. The localization of bFGF at the cell 
surface was taken as an indicator of bFGF translocation and subsequently release 
(as discussed above). Hence, that bFGF was measured at the cell surface after 
treatment of adherent cells but not of suspended cells indicates that elastase is not 
acting directly on the cells or their integrins but rather via the ECM. Taken into 
consideration that the signal from shear stress and elastase is transmitted to the cell 
through the same pathway, this observation is in agreement with the study showing 
that endothelial cells must be anchored to their matrix in order to sense and 
transduce signals in response to shear stress (Takahashi & Berk, 1996). This is supported 
by the finding by Jalali et. al 2001, who demonstrated that the shear stress induced 
mechanotransduction was abolished when new integrin-ECM ligand interactions 
were prevented (Jalali et al., 2001). Furthermore, another study showed that 
estrogen-mediated bFGF release from endothelial cells was significantly higher when 
the cells were seeded on ECM proteins such as collagen IV, laminin type I and 
fibronectin as compared with collagen I or pure plastic (Albuquerque et al., 1998).  
Moreover, it was demonstrated that whereas endothelial cells plated on fibronectin 
or fibrinogen respond to shear stress with an activation of NF-κB, cells grown on 
collagen or laminin did not (Orr et al., 2005). All these mentioned studies emphasize 
the importance of the interplay between cells and their matrix in terms of cellular 
response to mechano stimulation.  
 Taken together, the mechanotransduction seems to be dependent upon integrin 
activation. It has been suggested that integrins can be activated either by 
cleavage, as shown for the αIIb subunit of the platelet integrin αIIbβ3 (Si-Tahar et al., 
1997) or by phophorylation of the β3 subunit of the integrin αvβ3 (Blystone et al., 1996). 
However, clustering of the integrins into focal adhesion-like structures has also been 
proposed as an option for activation (Shyy & Chien, 2002; Giancotti & Ruoslahti, 
1999; Avalos et al., 2004; Weyts et al., 2002), a process which can be established as 
integrins bind to the ECM (Giancotti & Ruoslahti, 1999; Shyy & Chien, 2002). However, 
since integrins constantly undergo binding turnover (Davies, 1995) the adhesion to 
the ECM by itself does not seem to be the signal, but rather the availability of new 
binding sites for the integrins might be essential for the integrin activation and the 
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subsequently initiation of intracellular signaling cascade (Tzima et al., 2001; Kano et 
al., 2000; Tzima et al., 2002). New binding sites might be established by remodeling of 
the architectural fine structure within the ECM. Since elastase is able to produce 
fragments of laminin type I, the ECM protein primarily used in the present study, it is a 
possible candidate for activating integrins. Therefore, I propose that elastase, which 
is released and/or activated by shear stress exposure, cleaves the ECM and thereby 
liberates ECM fragtments or changes the matrix structure both of which are capable 
of activating the integrin αvβ3, presumably by changing their clustering. This integrin 
activation results in initiation of the specific intracellular signal cascade involving p38 
MAPK activation and HSP27 phosphorylation and translocation, since these events 
are abolished by integrin αvβ3 inhibition. Subsequently, this leads to the release of 
bFGF from the endothelial cells.  
 
Perspectives 
 
Basic FGF is, as already pointed out, implicated in a variety of physiological 
processes, in pathogenesis of vascular diseases as well as in tumor growth. The bFGF 
acts primarily as a paracrine factor (Nugent & Iozzo, 2000; Valverius et al., 1990) and 
hence, factors that lead to the release of bFGF from endothelial cells may not only 
facilitate tumor growth but also essential physiological processes such as 
development and angiogenesis. Hence, taking together, the knowledge about how 
bFGF is released may be very beneficial. The present study provides evidence for a 
role of elastase in mediating bFGF release from endothelial cells. Therefore, elastase 
and maybe other proteases, might be a key target in tumor growth as wells as a 
source to improve perfusion for example after myocardial ischemia. However, the 
organism is a complex system and thus, elastase may not only act on endothelial 
cells to release bFGF, but might also affect other proteins and systems. Hence, the 
interpretations of the role of elastase must be made with caution until its function has 
been verified in vivo. 
 With respect to physiologic remodelling processes, much interest has been 
focussed on shear stress induced vascular growth upon chronic increases in blood 
flow. It has been demonstrated that chronically decreased blood flow in vivo leads 
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to a reduction in the diameter of the artery (Langille & O'Donnell, 1986) and another 
study reports that the diameter is increased by chronically elevated blood flow 
(Tronc et al., 1996). Furthermore, the increased expression of bFGF in smooth muscle 
cells from rabbits has been shown to correlate with flow induced arterial 
enlargement (Singh et al., 1998). The present study and the study by Gloe et. al 
(2002) provides evidence for release of bFGF during shear stress in vitro. Exercise is a 
physiologic situation in which shear stress is elevated in vivo, and it has indeed been 
demonstrated that circulating bFGF is enhanced acutely after maximal exercise 
(Campuzano et al., 2002) as well as chronically after 6 months of exercise training 
(Seida et al., 2003). However, the relation between shear stress and bFGF in vivo is 
not entirely clear since other groups report of no change in exercise-induced 
circulating level bFGF (Adams et al., 2004; Gu et al., 2004) and again others 
observed even a decrease in the amount of bFGF within the first 10 min of exercise 
(Eliakim et al., 2000) followed by a increase in the level of bFGF after 130 min of 
exercise (Nemet et al., 2002). As it appears, inconsistencies exist regarding the bFGF 
respond to exercise, which could be explained by the fact that shear stress changes 
might have been different as they have not been really measured in most studies. 
Moreover, increased blood flow as a consequence of exercise not only affects the 
shear stress but also the pressure distribution along the vascular tree. Moreover, 
depending on the type of exercise, ischemia might also be a factor that influences 
bFGF release in vivo. Hence, the bFGF response is most likely dependent upon the 
type of exercise protocol utilized in the particular study, and it might therefore 
premature to associate increased flow in vivo always with increased bFGF release. 
 Angiogenesis is a second important focus with respect to bFGF effects in vivo. In 
fact, angiogenesis has been observed after 4 weeks of intensive one-legged 
exercise training, which correlated with an enhanced performance measured as the 
time to exhaustion during one-legged exercise (Jensen et al., 2004). A role of bFGF in 
exercise- and hence shear stress-induced angiogenesis is suggested by Lederman et. 
al (2002) who demonstrated that intra-arterial administration of recombinant bFGF 
leads to angiogenesis and a significant increase in peak walking time after 90 days 
(Lederman et al., 2002), supported by the finding that transendocardial 
administration of a recombinant gene coding for bFGF in patients with hibernating 
myocardium increased the perfusion and exercise tolerance (Kolomoets, 2001). 
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However, it is not generally accepted that bFGF is involved in initiation of 
angiogenesis (Brown et al., 1998). Since bFGF can induce the expression of VEGF in 
endothelial cells, VEGF could decisively modulate the apparent angiogenic activity 
of bFGF (Seghezzi et al., 1998). 
 
Summary and conclusions 
 
This study aimed to answer the question whether proteolytic remodeling of the 
extracellular matrix contributes to the shear stress-induced bFGF release. The results 
obtained in the present study present evidence for an important role of elastase as 
the protease which provides the link between the shear stress forces exerted on 
endothelial cells and the cellular response manifested as a release of bFGF. This 
Table 7: Comparison of results obtained from shear stress – either in the present study or from the 
literature – with results from exogenously added elastase. 
 
Shear stress exposure  
(16 dyn/cm2) 
Elastase treatment  
(0.5 U/ml) 
Treatment 
 
 
Examining 
Result 
Figure / 
reference 
Result 
Figure / 
reference 
bFGF release 
+ αvβ3 inhibition  
5 fold increase  
Reduction 
Fig. 16 
Gloe et al. 
2002 
2 fold increase  
Reduction 
Fig. 19 
Fig. 20 
bFGF cell surface localization 
+ αvβ3 inhibition  
Increase Fig. 21 1.5 fold increase  
Reduction 
Fig. 23A 
Fig. 23A 
HSP27 in membrane fraction 
(translocation) 
+ αvβ3 inhibition 
6 fold increase Fig. 29A 2.5 fold increase 
 
Reduced 
Fig. 29B 
 
Fig. 29B 
HSP27 phosphorylation 
 
+ αvβ3 inhibition  
 
+ p38 inhibition  
Increase 
 
Reduction  
 
Reduction  
Fig. 24 
 
Gloe et al 
2002 
Azuma et 
al.2001  
1.4 fold increase 
 
Reduction  
 
Reduction 
Fig. 
25+26A 
Fig. 26B 
 
Fig. 26B 
p38 phosphorylation 
 
+ αvβ3 inhibition  
Increase 
 
Azuma et 
al.2001 
2.8 fold increase 
 
Reduction 
Fig. 27A 
 
Fig. 27A 
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conclusion is based on the observations that shear stress and exogenously added 
elastase initiate the same subcellular signaling pathway (table 7). The present study 
reveals the following chain of events: Shear stress releases and/or activates elastase, 
which subsequently remodels the extracellular matrix. It remains to be clarified 
whether this occurs either by clustering the integrins as a consequence of altered 
matrix structure or by releasing a fragment in the matrix (matricryptin) that 
specifically stimulates αvβ3. The activation of the integrin initiates an intracellular 
signaling cascade involving phosphorylation of HSP27 via the p38 MAP kinase 
pathway. The phosphorylation of HSP27 is necessary for its interaction with bFGF. The 
translocation of this complex to the membrane is then a prerequisite for the release 
of bFGF which is not possible through the classical seretion pathway. A summary of 
the pathways initiated by shear stress and clarified in this study is schematically 
illustrated in figure 32.  
Figure 32. Proposed signaling pathway for shear stress-induced bFGF release: Shear stress forces 
on endothelial cells (1) induce an enhanced elastase activity (2). The elastase can activate 
integrin αvβ3 via the matrix (3) leading to p38 MAPK activation and subsequently 
phosphorylation of heat shock protein 27 (HSP27) (4). Following phosphorylation, HSP27 binds 
bFGF and translocate towards the plasma membrane (5), through where bFGF is released form 
the endothelial cells (6). 
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